AU2195395A - Synthetic peptide based immunogens for the treatment of allergy - Google Patents
Synthetic peptide based immunogens for the treatment of allergyInfo
- Publication number
- AU2195395A AU2195395A AU21953/95A AU2195395A AU2195395A AU 2195395 A AU2195395 A AU 2195395A AU 21953/95 A AU21953/95 A AU 21953/95A AU 2195395 A AU2195395 A AU 2195395A AU 2195395 A AU2195395 A AU 2195395A
- Authority
- AU
- Australia
- Prior art keywords
- gly
- lys
- phe
- val
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 327
- 206010020751 Hypersensitivity Diseases 0.000 title claims description 38
- 208000026935 allergic disease Diseases 0.000 title description 17
- 238000011282 treatment Methods 0.000 title description 15
- 230000007815 allergy Effects 0.000 title description 13
- 150000001413 amino acids Chemical class 0.000 claims description 134
- 230000002163 immunogen Effects 0.000 claims description 87
- 239000000203 mixture Substances 0.000 claims description 74
- 229960005486 vaccine Drugs 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 32
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 19
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 15
- 229930195729 fatty acid Natural products 0.000 claims description 15
- 239000000194 fatty acid Substances 0.000 claims description 15
- 150000004665 fatty acids Chemical class 0.000 claims description 15
- 101710198693 Invasin Proteins 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 229940024606 amino acid Drugs 0.000 description 135
- 235000001014 amino acid Nutrition 0.000 description 134
- 102000004196 processed proteins & peptides Human genes 0.000 description 48
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 40
- 241000700159 Rattus Species 0.000 description 35
- 239000002671 adjuvant Substances 0.000 description 23
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 21
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 21
- 230000003053 immunization Effects 0.000 description 21
- 238000002649 immunization Methods 0.000 description 21
- 229960001340 histamine Drugs 0.000 description 20
- 108010064235 lysylglycine Proteins 0.000 description 20
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 19
- GRVMHFCZUIYNKQ-UFYCRDLUSA-N Phe-Phe-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O GRVMHFCZUIYNKQ-UFYCRDLUSA-N 0.000 description 19
- 239000013566 allergen Substances 0.000 description 19
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 18
- 108010081551 glycylphenylalanine Proteins 0.000 description 18
- 210000003630 histaminocyte Anatomy 0.000 description 16
- 239000000427 antigen Substances 0.000 description 15
- 239000012636 effector Substances 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 13
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 210000003651 basophil Anatomy 0.000 description 13
- 239000011347 resin Substances 0.000 description 13
- 229920005989 resin Polymers 0.000 description 13
- 229940037003 alum Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 230000004936 stimulating effect Effects 0.000 description 12
- 230000005847 immunogenicity Effects 0.000 description 11
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 11
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 11
- 125000006850 spacer group Chemical group 0.000 description 11
- FEUPVVCGQLNXNP-IRXDYDNUSA-N Gly-Phe-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 FEUPVVCGQLNXNP-IRXDYDNUSA-N 0.000 description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 10
- FHIAJWBDZVHLAH-YUMQZZPRSA-N Lys-Gly-Ser Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FHIAJWBDZVHLAH-YUMQZZPRSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 230000002788 anti-peptide Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 238000009169 immunotherapy Methods 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 239000004472 Lysine Substances 0.000 description 9
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 229960003646 lysine Drugs 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
- FXGRXIATVXUAHO-WEDXCCLWSA-N Gly-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN FXGRXIATVXUAHO-WEDXCCLWSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 108010015792 glycyllysine Proteins 0.000 description 8
- 108010084572 phenylalanyl-valine Proteins 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- VDTYRPWRWRCROL-UFYCRDLUSA-N Phe-Val-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 VDTYRPWRWRCROL-UFYCRDLUSA-N 0.000 description 7
- JFWDJFULOLKQFY-QWRGUYRKSA-N Ser-Gly-Phe Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JFWDJFULOLKQFY-QWRGUYRKSA-N 0.000 description 7
- JLNMFGCJODTXDH-WEDXCCLWSA-N Thr-Lys-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O JLNMFGCJODTXDH-WEDXCCLWSA-N 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- OGPKMBOPMDTEDM-IHRRRGAJSA-N Tyr-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N OGPKMBOPMDTEDM-IHRRRGAJSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 6
- 108010050848 glycylleucine Proteins 0.000 description 6
- 108010037850 glycylvaline Proteins 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 108010054155 lysyllysine Proteins 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 5
- 241000700198 Cavia Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 description 5
- PBIPLDMFHAICIP-DCAQKATOSA-N Lys-Glu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PBIPLDMFHAICIP-DCAQKATOSA-N 0.000 description 5
- HAUUXTXKJNVIFY-ONGXEEELSA-N Lys-Gly-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAUUXTXKJNVIFY-ONGXEEELSA-N 0.000 description 5
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 5
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 5
- OJCISMMNNUNNJA-BZSNNMDCSA-N Tyr-Tyr-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=C(O)C=C1 OJCISMMNNUNNJA-BZSNNMDCSA-N 0.000 description 5
- OPGWZDIYEYJVRX-AVGNSLFASA-N Val-His-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N OPGWZDIYEYJVRX-AVGNSLFASA-N 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000036783 anaphylactic response Effects 0.000 description 5
- 208000003455 anaphylaxis Diseases 0.000 description 5
- 108010068265 aspartyltyrosine Proteins 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 229960002433 cysteine Drugs 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- HXNNRBHASOSVPG-GUBZILKMSA-N Ala-Glu-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HXNNRBHASOSVPG-GUBZILKMSA-N 0.000 description 4
- QITBQGJOXQYMOA-ZETCQYMHSA-N Gly-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CN QITBQGJOXQYMOA-ZETCQYMHSA-N 0.000 description 4
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- WQWSMEOYXJTFRU-GUBZILKMSA-N Leu-Glu-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O WQWSMEOYXJTFRU-GUBZILKMSA-N 0.000 description 4
- 241000712079 Measles morbillivirus Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 108010081690 Pertussis Toxin Proteins 0.000 description 4
- NAXPHWZXEXNDIW-JTQLQIEISA-N Phe-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 NAXPHWZXEXNDIW-JTQLQIEISA-N 0.000 description 4
- NLOAIFSWUUFQFR-CIUDSAMLSA-N Ser-Leu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O NLOAIFSWUUFQFR-CIUDSAMLSA-N 0.000 description 4
- 108010055044 Tetanus Toxin Proteins 0.000 description 4
- NRFTYDWKWGJLAR-MELADBBJSA-N Tyr-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O NRFTYDWKWGJLAR-MELADBBJSA-N 0.000 description 4
- UBTBGUDNDFZLGP-SRVKXCTJSA-N Val-Arg-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C(C)C)C(=O)O)N UBTBGUDNDFZLGP-SRVKXCTJSA-N 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000013401 experimental design Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 4
- 108010026333 seryl-proline Proteins 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000012453 sprague-dawley rat model Methods 0.000 description 4
- 229940118376 tetanus toxin Drugs 0.000 description 4
- -1 2,4- dichlorobenzyl Chemical group 0.000 description 3
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WCZXPVPHUMYLMS-VEVYYDQMSA-N Arg-Thr-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O WCZXPVPHUMYLMS-VEVYYDQMSA-N 0.000 description 3
- RYQSYXFGFOTJDJ-RHYQMDGZSA-N Arg-Thr-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O RYQSYXFGFOTJDJ-RHYQMDGZSA-N 0.000 description 3
- SUMJNGAMIQSNGX-TUAOUCFPSA-N Arg-Val-Pro Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N1CCC[C@@H]1C(O)=O SUMJNGAMIQSNGX-TUAOUCFPSA-N 0.000 description 3
- NVGWESORMHFISY-SRVKXCTJSA-N Asn-Asn-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NVGWESORMHFISY-SRVKXCTJSA-N 0.000 description 3
- DATSKXOXPUAOLK-KKUMJFAQSA-N Asn-Tyr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O DATSKXOXPUAOLK-KKUMJFAQSA-N 0.000 description 3
- MRQQMVZUHXUPEV-IHRRRGAJSA-N Asp-Arg-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MRQQMVZUHXUPEV-IHRRRGAJSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- XGIAHEUULGOZHH-GUBZILKMSA-N Cys-Arg-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N XGIAHEUULGOZHH-GUBZILKMSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- OGNJZUXUTPQVBR-BQBZGAKWSA-N Glu-Gly-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OGNJZUXUTPQVBR-BQBZGAKWSA-N 0.000 description 3
- HRBYTAIBKPNZKQ-AVGNSLFASA-N Glu-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O HRBYTAIBKPNZKQ-AVGNSLFASA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- QIZJOTQTCAGKPU-KWQFWETISA-N Gly-Ala-Tyr Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 QIZJOTQTCAGKPU-KWQFWETISA-N 0.000 description 3
- PCPOYRCAHPJXII-UWVGGRQHSA-N Gly-Lys-Met Chemical group [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O PCPOYRCAHPJXII-UWVGGRQHSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- XGBVLRJLHUVCNK-DCAQKATOSA-N His-Val-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O XGBVLRJLHUVCNK-DCAQKATOSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241000880493 Leptailurus serval Species 0.000 description 3
- JDBQSGMJBMPNFT-AVGNSLFASA-N Leu-Pro-Val Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O JDBQSGMJBMPNFT-AVGNSLFASA-N 0.000 description 3
- JIHDFWWRYHSAQB-GUBZILKMSA-N Leu-Ser-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JIHDFWWRYHSAQB-GUBZILKMSA-N 0.000 description 3
- LRKCBIUDWAXNEG-CSMHCCOUSA-N Leu-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRKCBIUDWAXNEG-CSMHCCOUSA-N 0.000 description 3
- ZDJQVSIPFLMNOX-RHYQMDGZSA-N Leu-Thr-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N ZDJQVSIPFLMNOX-RHYQMDGZSA-N 0.000 description 3
- MPOHDJKRBLVGCT-CIUDSAMLSA-N Lys-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N MPOHDJKRBLVGCT-CIUDSAMLSA-N 0.000 description 3
- ISHNZELVUVPCHY-ZETCQYMHSA-N Lys-Gly-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O ISHNZELVUVPCHY-ZETCQYMHSA-N 0.000 description 3
- XIZQPFCRXLUNMK-BZSNNMDCSA-N Lys-Leu-Phe Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCCCN)N XIZQPFCRXLUNMK-BZSNNMDCSA-N 0.000 description 3
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 3
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 3
- ATNKHRAIZCMCCN-BZSNNMDCSA-N Lys-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N ATNKHRAIZCMCCN-BZSNNMDCSA-N 0.000 description 3
- AXIOGMQCDYVTNY-ACRUOGEOSA-N Phe-Phe-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 AXIOGMQCDYVTNY-ACRUOGEOSA-N 0.000 description 3
- AOKZOUGUMLBPSS-PMVMPFDFSA-N Phe-Trp-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O AOKZOUGUMLBPSS-PMVMPFDFSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- BYIROAKULFFTEK-CIUDSAMLSA-N Ser-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO BYIROAKULFFTEK-CIUDSAMLSA-N 0.000 description 3
- WGDYNRCOQRERLZ-KKUMJFAQSA-N Ser-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N WGDYNRCOQRERLZ-KKUMJFAQSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- ASJDFGOPDCVXTG-KATARQTJSA-N Thr-Cys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O ASJDFGOPDCVXTG-KATARQTJSA-N 0.000 description 3
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 3
- 241000607734 Yersinia <bacteria> Species 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 108010087924 alanylproline Proteins 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- 108010089804 glycyl-threonine Proteins 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 210000004201 immune sera Anatomy 0.000 description 3
- 229940042743 immune sera Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 108010009298 lysylglutamic acid Proteins 0.000 description 3
- 229940023041 peptide vaccine Drugs 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 229960001153 serine Drugs 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- WRDANSJTFOHBPI-FXQIFTODSA-N Ala-Arg-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N WRDANSJTFOHBPI-FXQIFTODSA-N 0.000 description 2
- NHCPCLJZRSIDHS-ZLUOBGJFSA-N Ala-Asp-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O NHCPCLJZRSIDHS-ZLUOBGJFSA-N 0.000 description 2
- HHRAXZAYZFFRAM-CIUDSAMLSA-N Ala-Leu-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O HHRAXZAYZFFRAM-CIUDSAMLSA-N 0.000 description 2
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 2
- FUKFQILQFQKHLE-DCAQKATOSA-N Ala-Lys-Met Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O FUKFQILQFQKHLE-DCAQKATOSA-N 0.000 description 2
- VQAVBBCZFQAAED-FXQIFTODSA-N Ala-Pro-Asn Chemical compound C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)N)C(=O)O)N VQAVBBCZFQAAED-FXQIFTODSA-N 0.000 description 2
- NHWYNIZWLJYZAG-XVYDVKMFSA-N Ala-Ser-His Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N NHWYNIZWLJYZAG-XVYDVKMFSA-N 0.000 description 2
- IYKVSFNGSWTTNZ-GUBZILKMSA-N Ala-Val-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IYKVSFNGSWTTNZ-GUBZILKMSA-N 0.000 description 2
- 241000380131 Ammophila arenaria Species 0.000 description 2
- YWENWUYXQUWRHQ-LPEHRKFASA-N Arg-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O YWENWUYXQUWRHQ-LPEHRKFASA-N 0.000 description 2
- PNIGSVZJNVUVJA-BQBZGAKWSA-N Arg-Gly-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O PNIGSVZJNVUVJA-BQBZGAKWSA-N 0.000 description 2
- KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 2
- XEOXPCNONWHHSW-AVGNSLFASA-N Arg-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N XEOXPCNONWHHSW-AVGNSLFASA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 240000003291 Armoracia rusticana Species 0.000 description 2
- SWLOHUMCUDRTCL-ZLUOBGJFSA-N Asn-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N SWLOHUMCUDRTCL-ZLUOBGJFSA-N 0.000 description 2
- LEFKSBYHUGUWLP-ACZMJKKPSA-N Asn-Ala-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LEFKSBYHUGUWLP-ACZMJKKPSA-N 0.000 description 2
- IARGXWMWRFOQPG-GCJQMDKQSA-N Asn-Ala-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IARGXWMWRFOQPG-GCJQMDKQSA-N 0.000 description 2
- RAQMSGVCGSJKCL-FOHZUACHSA-N Asn-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(N)=O RAQMSGVCGSJKCL-FOHZUACHSA-N 0.000 description 2
- HDHZCEDPLTVHFZ-GUBZILKMSA-N Asn-Leu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O HDHZCEDPLTVHFZ-GUBZILKMSA-N 0.000 description 2
- WQAOZCVOOYUWKG-LSJOCFKGSA-N Asn-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CC(=O)N)N WQAOZCVOOYUWKG-LSJOCFKGSA-N 0.000 description 2
- SVFOIXMRMLROHO-SRVKXCTJSA-N Asp-Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SVFOIXMRMLROHO-SRVKXCTJSA-N 0.000 description 2
- BRRPVTUFESPTCP-ACZMJKKPSA-N Asp-Ser-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O BRRPVTUFESPTCP-ACZMJKKPSA-N 0.000 description 2
- QOJJMJKTMKNFEF-ZKWXMUAHSA-N Asp-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O QOJJMJKTMKNFEF-ZKWXMUAHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 2
- OQXDUSZKISQQSS-GUBZILKMSA-N Glu-Lys-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OQXDUSZKISQQSS-GUBZILKMSA-N 0.000 description 2
- JWNZHMSRZXXGTM-XKBZYTNZSA-N Glu-Ser-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JWNZHMSRZXXGTM-XKBZYTNZSA-N 0.000 description 2
- XCLCVBYNGXEVDU-WHFBIAKZSA-N Gly-Asn-Ser Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O XCLCVBYNGXEVDU-WHFBIAKZSA-N 0.000 description 2
- DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 description 2
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 description 2
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 2
- DNVDEMWIYLVIQU-RCOVLWMOSA-N Gly-Val-Asp Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O DNVDEMWIYLVIQU-RCOVLWMOSA-N 0.000 description 2
- QPSCMXDWVKWVOW-BZSNNMDCSA-N His-His-Tyr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QPSCMXDWVKWVOW-BZSNNMDCSA-N 0.000 description 2
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- VIWUBXKCYJGNCL-SRVKXCTJSA-N Leu-Asn-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 VIWUBXKCYJGNCL-SRVKXCTJSA-N 0.000 description 2
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 2
- UCNNZELZXFXXJQ-BZSNNMDCSA-N Leu-Leu-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCNNZELZXFXXJQ-BZSNNMDCSA-N 0.000 description 2
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 2
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108010028921 Lipopeptides Proteins 0.000 description 2
- RVOMPSJXSRPFJT-DCAQKATOSA-N Lys-Ala-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RVOMPSJXSRPFJT-DCAQKATOSA-N 0.000 description 2
- CUHGAUZONORRIC-HJGDQZAQSA-N Lys-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N)O CUHGAUZONORRIC-HJGDQZAQSA-N 0.000 description 2
- VHTOGMKQXXJOHG-RHYQMDGZSA-N Lys-Thr-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O VHTOGMKQXXJOHG-RHYQMDGZSA-N 0.000 description 2
- KDBDVESGGJYVEH-PMVMPFDFSA-N Lys-Trp-Phe Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCCN)C(O)=O)C1=CC=CC=C1 KDBDVESGGJYVEH-PMVMPFDFSA-N 0.000 description 2
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- FRPVPGRXUKFEQE-YDHLFZDLSA-N Phe-Asp-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O FRPVPGRXUKFEQE-YDHLFZDLSA-N 0.000 description 2
- PSBJZLMFFTULDX-IXOXFDKPSA-N Phe-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=CC=C1)N)O PSBJZLMFFTULDX-IXOXFDKPSA-N 0.000 description 2
- NPLGQVKZFGJWAI-QWHCGFSZSA-N Phe-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O NPLGQVKZFGJWAI-QWHCGFSZSA-N 0.000 description 2
- NJJBATPLUQHRBM-IHRRRGAJSA-N Phe-Pro-Ser Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@@H](CO)C(=O)O NJJBATPLUQHRBM-IHRRRGAJSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- XROLYVMNVIKVEM-BQBZGAKWSA-N Pro-Asn-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O XROLYVMNVIKVEM-BQBZGAKWSA-N 0.000 description 2
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 2
- CLJLVCYFABNTHP-DCAQKATOSA-N Pro-Leu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O CLJLVCYFABNTHP-DCAQKATOSA-N 0.000 description 2
- RFWXYTJSVDUBBZ-DCAQKATOSA-N Pro-Pro-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RFWXYTJSVDUBBZ-DCAQKATOSA-N 0.000 description 2
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 2
- LAFKUZYWNCHOHT-WHFBIAKZSA-N Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O LAFKUZYWNCHOHT-WHFBIAKZSA-N 0.000 description 2
- XXNYYSXNXCJYKX-DCAQKATOSA-N Ser-Leu-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O XXNYYSXNXCJYKX-DCAQKATOSA-N 0.000 description 2
- GVMUJUPXFQFBBZ-GUBZILKMSA-N Ser-Lys-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GVMUJUPXFQFBBZ-GUBZILKMSA-N 0.000 description 2
- CRJZZXMAADSBBQ-SRVKXCTJSA-N Ser-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO CRJZZXMAADSBBQ-SRVKXCTJSA-N 0.000 description 2
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 2
- KKKVOZNCLALMPV-XKBZYTNZSA-N Ser-Thr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KKKVOZNCLALMPV-XKBZYTNZSA-N 0.000 description 2
- ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 description 2
- ZUXQFMVPAYGPFJ-JXUBOQSCSA-N Thr-Ala-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN ZUXQFMVPAYGPFJ-JXUBOQSCSA-N 0.000 description 2
- CAGTXGDOIFXLPC-KZVJFYERSA-N Thr-Arg-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CCCN=C(N)N CAGTXGDOIFXLPC-KZVJFYERSA-N 0.000 description 2
- JNQZPAWOPBZGIX-RCWTZXSCSA-N Thr-Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)O)CCCN=C(N)N JNQZPAWOPBZGIX-RCWTZXSCSA-N 0.000 description 2
- QGXCWPNQVCYJEL-NUMRIWBASA-N Thr-Asn-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QGXCWPNQVCYJEL-NUMRIWBASA-N 0.000 description 2
- JBHMLZSKIXMVFS-XVSYOHENSA-N Thr-Asn-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JBHMLZSKIXMVFS-XVSYOHENSA-N 0.000 description 2
- ONNSECRQFSTMCC-XKBZYTNZSA-N Thr-Glu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ONNSECRQFSTMCC-XKBZYTNZSA-N 0.000 description 2
- XFTYVCHLARBHBQ-FOHZUACHSA-N Thr-Gly-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O XFTYVCHLARBHBQ-FOHZUACHSA-N 0.000 description 2
- YUPVPKZBKCLFLT-QTKMDUPCSA-N Thr-His-Val Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N)O YUPVPKZBKCLFLT-QTKMDUPCSA-N 0.000 description 2
- APIDTRXFGYOLLH-VQVTYTSYSA-N Thr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)[C@@H](C)O APIDTRXFGYOLLH-VQVTYTSYSA-N 0.000 description 2
- GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 description 2
- UQCNIMDPYICBTR-KYNKHSRBSA-N Thr-Thr-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UQCNIMDPYICBTR-KYNKHSRBSA-N 0.000 description 2
- JAWUQFCGNVEDRN-MEYUZBJRSA-N Thr-Tyr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O JAWUQFCGNVEDRN-MEYUZBJRSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- GKUROEIXVURAAO-BPUTZDHNSA-N Trp-Asp-Arg Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GKUROEIXVURAAO-BPUTZDHNSA-N 0.000 description 2
- HJWLQSFTGDQSRX-BPUTZDHNSA-N Trp-Met-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O HJWLQSFTGDQSRX-BPUTZDHNSA-N 0.000 description 2
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- PRONOHBTMLNXCZ-BZSNNMDCSA-N Tyr-Leu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PRONOHBTMLNXCZ-BZSNNMDCSA-N 0.000 description 2
- XUIOBCQESNDTDE-FQPOAREZSA-N Tyr-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O XUIOBCQESNDTDE-FQPOAREZSA-N 0.000 description 2
- 108010064997 VPY tripeptide Proteins 0.000 description 2
- OQWNEUXPKHIEJO-NRPADANISA-N Val-Glu-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N OQWNEUXPKHIEJO-NRPADANISA-N 0.000 description 2
- XBRMBDFYOFARST-AVGNSLFASA-N Val-His-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N XBRMBDFYOFARST-AVGNSLFASA-N 0.000 description 2
- AGXGCFSECFQMKB-NHCYSSNCSA-N Val-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N AGXGCFSECFQMKB-NHCYSSNCSA-N 0.000 description 2
- RWOGENDAOGMHLX-DCAQKATOSA-N Val-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N RWOGENDAOGMHLX-DCAQKATOSA-N 0.000 description 2
- CKTMJBPRVQWPHU-JSGCOSHPSA-N Val-Phe-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)O)N CKTMJBPRVQWPHU-JSGCOSHPSA-N 0.000 description 2
- QWCZXKIFPWPQHR-JYJNAYRXSA-N Val-Pro-Tyr Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QWCZXKIFPWPQHR-JYJNAYRXSA-N 0.000 description 2
- QTPQHINADBYBNA-DCAQKATOSA-N Val-Ser-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN QTPQHINADBYBNA-DCAQKATOSA-N 0.000 description 2
- OFTXTCGQJXTNQS-XGEHTFHBSA-N Val-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N)O OFTXTCGQJXTNQS-XGEHTFHBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 108010036533 arginylvaline Proteins 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 108010038633 aspartylglutamate Proteins 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 108010060199 cysteinylproline Proteins 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- 229940124581 decongestants Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 108010087823 glycyltyrosine Proteins 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 108010018006 histidylserine Proteins 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 108010012058 leucyltyrosine Proteins 0.000 description 2
- 108010003700 lysyl aspartic acid Proteins 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 108010056582 methionylglutamic acid Proteins 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 108010070643 prolylglutamic acid Proteins 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- PZFZLRNAOHUQPH-GOOVXGPGSA-N (2r)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CSCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PZFZLRNAOHUQPH-GOOVXGPGSA-N 0.000 description 1
- PILPQAMQDMXSBY-NSHDSACASA-N (2s)-6-amino-2-[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]hexanoic acid Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)[C@H](C(O)=O)CCCCN PILPQAMQDMXSBY-NSHDSACASA-N 0.000 description 1
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- KVWLTGNCJYDJET-LSJOCFKGSA-N Ala-Arg-His Chemical compound C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KVWLTGNCJYDJET-LSJOCFKGSA-N 0.000 description 1
- CXZFXHGJJPVUJE-CIUDSAMLSA-N Ala-Cys-Leu Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)O)N CXZFXHGJJPVUJE-CIUDSAMLSA-N 0.000 description 1
- YEVZMOUUZINZCK-LKTVYLICSA-N Ala-Glu-Trp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O YEVZMOUUZINZCK-LKTVYLICSA-N 0.000 description 1
- OINVDEKBKBCPLX-JXUBOQSCSA-N Ala-Lys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OINVDEKBKBCPLX-JXUBOQSCSA-N 0.000 description 1
- HYIDEIQUCBKIPL-CQDKDKBSSA-N Ala-Phe-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N HYIDEIQUCBKIPL-CQDKDKBSSA-N 0.000 description 1
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 1
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 description 1
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 1
- AENHOIXXHKNIQL-AUTRQRHGSA-N Ala-Tyr-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H]([NH3+])C)CC1=CC=C(O)C=C1 AENHOIXXHKNIQL-AUTRQRHGSA-N 0.000 description 1
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 1
- KJGNDQCYBNBXDA-GUBZILKMSA-N Arg-Arg-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N KJGNDQCYBNBXDA-GUBZILKMSA-N 0.000 description 1
- NONSEUUPKITYQT-BQBZGAKWSA-N Arg-Asn-Gly Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)N)CN=C(N)N NONSEUUPKITYQT-BQBZGAKWSA-N 0.000 description 1
- SQKPKIJVWHAWNF-DCAQKATOSA-N Arg-Asp-Lys Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O SQKPKIJVWHAWNF-DCAQKATOSA-N 0.000 description 1
- TTXYKSADPSNOIF-IHRRRGAJSA-N Arg-Asp-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O TTXYKSADPSNOIF-IHRRRGAJSA-N 0.000 description 1
- NKNILFJYKKHBKE-WPRPVWTQSA-N Arg-Gly-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NKNILFJYKKHBKE-WPRPVWTQSA-N 0.000 description 1
- OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 description 1
- JEXPNDORFYHJTM-IHRRRGAJSA-N Arg-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCN=C(N)N JEXPNDORFYHJTM-IHRRRGAJSA-N 0.000 description 1
- JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 description 1
- BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 1
- NPAVRDPEFVKELR-DCAQKATOSA-N Arg-Lys-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NPAVRDPEFVKELR-DCAQKATOSA-N 0.000 description 1
- LRPZJPMQGKGHSG-XGEHTFHBSA-N Arg-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N)O LRPZJPMQGKGHSG-XGEHTFHBSA-N 0.000 description 1
- ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 description 1
- OGZBJJLRKQZRHL-KJEVXHAQSA-N Arg-Thr-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OGZBJJLRKQZRHL-KJEVXHAQSA-N 0.000 description 1
- NPDLYUOYAGBHFB-WDSKDSINSA-N Asn-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NPDLYUOYAGBHFB-WDSKDSINSA-N 0.000 description 1
- WVCJSDCHTUTONA-FXQIFTODSA-N Asn-Asp-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WVCJSDCHTUTONA-FXQIFTODSA-N 0.000 description 1
- DMLSCRJBWUEALP-LAEOZQHASA-N Asn-Glu-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O DMLSCRJBWUEALP-LAEOZQHASA-N 0.000 description 1
- CTQIOCMSIJATNX-WHFBIAKZSA-N Asn-Gly-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O CTQIOCMSIJATNX-WHFBIAKZSA-N 0.000 description 1
- FTCGGKNCJZOPNB-WHFBIAKZSA-N Asn-Gly-Ser Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FTCGGKNCJZOPNB-WHFBIAKZSA-N 0.000 description 1
- ZMUQQMGITUJQTI-CIUDSAMLSA-N Asn-Leu-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O ZMUQQMGITUJQTI-CIUDSAMLSA-N 0.000 description 1
- YUUIAUXBNOHFRJ-IHRRRGAJSA-N Asn-Phe-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O YUUIAUXBNOHFRJ-IHRRRGAJSA-N 0.000 description 1
- FTNRWCPWDWRPAV-BZSNNMDCSA-N Asn-Phe-Phe Chemical compound C([C@H](NC(=O)[C@H](CC(N)=O)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 FTNRWCPWDWRPAV-BZSNNMDCSA-N 0.000 description 1
- HPBNLFLSSQDFQW-WHFBIAKZSA-N Asn-Ser-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O HPBNLFLSSQDFQW-WHFBIAKZSA-N 0.000 description 1
- VPPXTHJNTYDNFJ-CIUDSAMLSA-N Asp-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N VPPXTHJNTYDNFJ-CIUDSAMLSA-N 0.000 description 1
- JGDBHIVECJGXJA-FXQIFTODSA-N Asp-Asp-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JGDBHIVECJGXJA-FXQIFTODSA-N 0.000 description 1
- OMMIEVATLAGRCK-BYPYZUCNSA-N Asp-Gly-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)NCC(O)=O OMMIEVATLAGRCK-BYPYZUCNSA-N 0.000 description 1
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 1
- CRNKLABLTICXDV-GUBZILKMSA-N Asp-His-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N CRNKLABLTICXDV-GUBZILKMSA-N 0.000 description 1
- UBPMOJLRVMGTOQ-GARJFASQSA-N Asp-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)O)N)C(=O)O UBPMOJLRVMGTOQ-GARJFASQSA-N 0.000 description 1
- BWJZSLQJNBSUPM-FXQIFTODSA-N Asp-Pro-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O BWJZSLQJNBSUPM-FXQIFTODSA-N 0.000 description 1
- YIDFBWRHIYOYAA-LKXGYXEUSA-N Asp-Ser-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YIDFBWRHIYOYAA-LKXGYXEUSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 102100021277 Beta-secretase 2 Human genes 0.000 description 1
- 101710150190 Beta-secretase 2 Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108700042132 Chlamydia trachomatis omp1 Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- QFMCHXSGIZPBKG-ZLUOBGJFSA-N Cys-Ala-Asp Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CS)N QFMCHXSGIZPBKG-ZLUOBGJFSA-N 0.000 description 1
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 1
- DZLQXIFVQFTFJY-BYPYZUCNSA-N Cys-Gly-Gly Chemical compound SC[C@H](N)C(=O)NCC(=O)NCC(O)=O DZLQXIFVQFTFJY-BYPYZUCNSA-N 0.000 description 1
- OHLLDUNVMPPUMD-DCAQKATOSA-N Cys-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N OHLLDUNVMPPUMD-DCAQKATOSA-N 0.000 description 1
- WZJLBUPPZRZNTO-CIUDSAMLSA-N Cys-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N WZJLBUPPZRZNTO-CIUDSAMLSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101100425960 Escherichia coli traT gene Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HJIFPJUEOGZWRI-GUBZILKMSA-N Glu-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N HJIFPJUEOGZWRI-GUBZILKMSA-N 0.000 description 1
- QQLBPVKLJBAXBS-FXQIFTODSA-N Glu-Glu-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O QQLBPVKLJBAXBS-FXQIFTODSA-N 0.000 description 1
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 1
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 1
- XMPAXPSENRSOSV-RYUDHWBXSA-N Glu-Gly-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XMPAXPSENRSOSV-RYUDHWBXSA-N 0.000 description 1
- YBAFDPFAUTYYRW-YUMQZZPRSA-N Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O YBAFDPFAUTYYRW-YUMQZZPRSA-N 0.000 description 1
- VSRCAOIHMGCIJK-SRVKXCTJSA-N Glu-Leu-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VSRCAOIHMGCIJK-SRVKXCTJSA-N 0.000 description 1
- ATVYZJGOZLVXDK-IUCAKERBSA-N Glu-Leu-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O ATVYZJGOZLVXDK-IUCAKERBSA-N 0.000 description 1
- IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 1
- SWRVAQHFBRZVNX-GUBZILKMSA-N Glu-Lys-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O SWRVAQHFBRZVNX-GUBZILKMSA-N 0.000 description 1
- CUPSDFQZTVVTSK-GUBZILKMSA-N Glu-Lys-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O CUPSDFQZTVVTSK-GUBZILKMSA-N 0.000 description 1
- TWYFJOHWGCCRIR-DCAQKATOSA-N Glu-Pro-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O TWYFJOHWGCCRIR-DCAQKATOSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- UXJHNZODTMHWRD-WHFBIAKZSA-N Gly-Asn-Ala Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O UXJHNZODTMHWRD-WHFBIAKZSA-N 0.000 description 1
- MFBYPDKTAJXHNI-VKHMYHEASA-N Gly-Cys Chemical compound [NH3+]CC(=O)N[C@@H](CS)C([O-])=O MFBYPDKTAJXHNI-VKHMYHEASA-N 0.000 description 1
- GZBZACMXFIPIDX-WHFBIAKZSA-N Gly-Cys-Asp Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)CN)C(=O)O GZBZACMXFIPIDX-WHFBIAKZSA-N 0.000 description 1
- CEXINUGNTZFNRY-BYPYZUCNSA-N Gly-Cys-Gly Chemical compound [NH3+]CC(=O)N[C@@H](CS)C(=O)NCC([O-])=O CEXINUGNTZFNRY-BYPYZUCNSA-N 0.000 description 1
- HDNXXTBKOJKWNN-WDSKDSINSA-N Gly-Glu-Asn Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O HDNXXTBKOJKWNN-WDSKDSINSA-N 0.000 description 1
- HPAIKDPJURGQLN-KBPBESRZSA-N Gly-His-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 HPAIKDPJURGQLN-KBPBESRZSA-N 0.000 description 1
- QSVMIMFAAZPCAQ-PMVVWTBXSA-N Gly-His-Thr Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QSVMIMFAAZPCAQ-PMVVWTBXSA-N 0.000 description 1
- MHXKHKWHPNETGG-QWRGUYRKSA-N Gly-Lys-Leu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O MHXKHKWHPNETGG-QWRGUYRKSA-N 0.000 description 1
- WDEHMRNSGHVNOH-VHSXEESVSA-N Gly-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)CN)C(=O)O WDEHMRNSGHVNOH-VHSXEESVSA-N 0.000 description 1
- NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 1
- IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 1
- YXTFLTJYLIAZQG-FJXKBIBVSA-N Gly-Thr-Arg Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YXTFLTJYLIAZQG-FJXKBIBVSA-N 0.000 description 1
- COZMNNJEGNPDED-HOCLYGCPSA-N Gly-Val-Trp Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O COZMNNJEGNPDED-HOCLYGCPSA-N 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- JHVCZQFWRLHUQR-DCAQKATOSA-N His-Arg-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N JHVCZQFWRLHUQR-DCAQKATOSA-N 0.000 description 1
- HIAHVKLTHNOENC-HGNGGELXSA-N His-Glu-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HIAHVKLTHNOENC-HGNGGELXSA-N 0.000 description 1
- CTJHHEQNUNIYNN-SRVKXCTJSA-N His-His-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O CTJHHEQNUNIYNN-SRVKXCTJSA-N 0.000 description 1
- SKOKHBGDXGTDDP-MELADBBJSA-N His-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N SKOKHBGDXGTDDP-MELADBBJSA-N 0.000 description 1
- ULRFSEJGSHYLQI-YESZJQIVSA-N His-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CN=CN3)N)C(=O)O ULRFSEJGSHYLQI-YESZJQIVSA-N 0.000 description 1
- ILUVWFTXAUYOBW-CUJWVEQBSA-N His-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CN=CN1)N)O ILUVWFTXAUYOBW-CUJWVEQBSA-N 0.000 description 1
- FCPSGEVYIVXPPO-QTKMDUPCSA-N His-Thr-Arg Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FCPSGEVYIVXPPO-QTKMDUPCSA-N 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
- KSZCCRIGNVSHFH-UWVGGRQHSA-N Leu-Arg-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O KSZCCRIGNVSHFH-UWVGGRQHSA-N 0.000 description 1
- MLTRLIITQPXHBJ-BQBZGAKWSA-N Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O MLTRLIITQPXHBJ-BQBZGAKWSA-N 0.000 description 1
- VCSBGUACOYUIGD-CIUDSAMLSA-N Leu-Asn-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VCSBGUACOYUIGD-CIUDSAMLSA-N 0.000 description 1
- DLCOFDAHNMMQPP-SRVKXCTJSA-N Leu-Asp-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DLCOFDAHNMMQPP-SRVKXCTJSA-N 0.000 description 1
- PPBKJAQJAUHZKX-SRVKXCTJSA-N Leu-Cys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC(C)C PPBKJAQJAUHZKX-SRVKXCTJSA-N 0.000 description 1
- HVJVUYQWFYMGJS-GVXVVHGQSA-N Leu-Glu-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O HVJVUYQWFYMGJS-GVXVVHGQSA-N 0.000 description 1
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 1
- VCHVSKNMTXWIIP-SRVKXCTJSA-N Leu-Lys-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O VCHVSKNMTXWIIP-SRVKXCTJSA-N 0.000 description 1
- OVZLLFONXILPDZ-VOAKCMCISA-N Leu-Lys-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OVZLLFONXILPDZ-VOAKCMCISA-N 0.000 description 1
- PKKMDPNFGULLNQ-AVGNSLFASA-N Leu-Met-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O PKKMDPNFGULLNQ-AVGNSLFASA-N 0.000 description 1
- BMVFXOQHDQZAQU-DCAQKATOSA-N Leu-Pro-Asp Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N BMVFXOQHDQZAQU-DCAQKATOSA-N 0.000 description 1
- IDGZVZJLYFTXSL-DCAQKATOSA-N Leu-Ser-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IDGZVZJLYFTXSL-DCAQKATOSA-N 0.000 description 1
- IZPVWNSAVUQBGP-CIUDSAMLSA-N Leu-Ser-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IZPVWNSAVUQBGP-CIUDSAMLSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 1
- SUYRAPCRSCCPAK-VFAJRCTISA-N Leu-Trp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SUYRAPCRSCCPAK-VFAJRCTISA-N 0.000 description 1
- VJGQRELPQWNURN-JYJNAYRXSA-N Leu-Tyr-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O VJGQRELPQWNURN-JYJNAYRXSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- ZQCVMVCVPFYXHZ-SRVKXCTJSA-N Lys-Asn-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCCN ZQCVMVCVPFYXHZ-SRVKXCTJSA-N 0.000 description 1
- CANPXOLVTMKURR-WEDXCCLWSA-N Lys-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN CANPXOLVTMKURR-WEDXCCLWSA-N 0.000 description 1
- PRCHKVGXZVTALR-KKUMJFAQSA-N Lys-His-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CCCCN)N PRCHKVGXZVTALR-KKUMJFAQSA-N 0.000 description 1
- CTBMEDOQJFGNMI-IHPCNDPISA-N Lys-His-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCCN)N CTBMEDOQJFGNMI-IHPCNDPISA-N 0.000 description 1
- PLDJDCJLRCYPJB-VOAKCMCISA-N Lys-Lys-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PLDJDCJLRCYPJB-VOAKCMCISA-N 0.000 description 1
- AFLBTVGQCQLOFJ-AVGNSLFASA-N Lys-Pro-Arg Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AFLBTVGQCQLOFJ-AVGNSLFASA-N 0.000 description 1
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- BKWJQWJPZMUWEG-LFSVMHDDSA-N Phe-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BKWJQWJPZMUWEG-LFSVMHDDSA-N 0.000 description 1
- RIYZXJVARWJLKS-KKUMJFAQSA-N Phe-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RIYZXJVARWJLKS-KKUMJFAQSA-N 0.000 description 1
- WKLMCMXFMQEKCX-SLFFLAALSA-N Phe-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O WKLMCMXFMQEKCX-SLFFLAALSA-N 0.000 description 1
- WEDZFLRYSIDIRX-IHRRRGAJSA-N Phe-Ser-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 WEDZFLRYSIDIRX-IHRRRGAJSA-N 0.000 description 1
- YDUGVDGFKNXFPL-IXOXFDKPSA-N Phe-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O YDUGVDGFKNXFPL-IXOXFDKPSA-N 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- LCRSGSIRKLXZMZ-BPNCWPANSA-N Pro-Ala-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LCRSGSIRKLXZMZ-BPNCWPANSA-N 0.000 description 1
- NHDVNAKDACFHPX-GUBZILKMSA-N Pro-Arg-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O NHDVNAKDACFHPX-GUBZILKMSA-N 0.000 description 1
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 1
- QSKCKTUQPICLSO-AVGNSLFASA-N Pro-Arg-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O QSKCKTUQPICLSO-AVGNSLFASA-N 0.000 description 1
- UVKNEILZSJMKSR-FXQIFTODSA-N Pro-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1 UVKNEILZSJMKSR-FXQIFTODSA-N 0.000 description 1
- HXOLCSYHGRNXJJ-IHRRRGAJSA-N Pro-Asp-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HXOLCSYHGRNXJJ-IHRRRGAJSA-N 0.000 description 1
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 1
- ZTVCLZLGHZXLOT-ULQDDVLXSA-N Pro-Glu-Trp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O ZTVCLZLGHZXLOT-ULQDDVLXSA-N 0.000 description 1
- UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 description 1
- DXTOOBDIIAJZBJ-BQBZGAKWSA-N Pro-Gly-Ser Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(O)=O DXTOOBDIIAJZBJ-BQBZGAKWSA-N 0.000 description 1
- RMODQFBNDDENCP-IHRRRGAJSA-N Pro-Lys-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O RMODQFBNDDENCP-IHRRRGAJSA-N 0.000 description 1
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 1
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 1
- RCYUBVHMVUHEBM-RCWTZXSCSA-N Pro-Pro-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RCYUBVHMVUHEBM-RCWTZXSCSA-N 0.000 description 1
- RTQKBZIRDWZLDF-BZSNNMDCSA-N Pro-Pro-Trp Chemical compound C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)O)CCN1C(=O)[C@@H]1CCCN1 RTQKBZIRDWZLDF-BZSNNMDCSA-N 0.000 description 1
- SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 101000801721 Schistosoma mansoni Triosephosphate isomerase Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 1
- PZZJMBYSYAKYPK-UWJYBYFXSA-N Ser-Ala-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PZZJMBYSYAKYPK-UWJYBYFXSA-N 0.000 description 1
- DKKGAAJTDKHWOD-BIIVOSGPSA-N Ser-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)C(=O)O DKKGAAJTDKHWOD-BIIVOSGPSA-N 0.000 description 1
- RDFQNDHEHVSONI-ZLUOBGJFSA-N Ser-Asn-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDFQNDHEHVSONI-ZLUOBGJFSA-N 0.000 description 1
- MESDJCNHLZBMEP-ZLUOBGJFSA-N Ser-Asp-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MESDJCNHLZBMEP-ZLUOBGJFSA-N 0.000 description 1
- CICQXRWZNVXFCU-SRVKXCTJSA-N Ser-His-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O CICQXRWZNVXFCU-SRVKXCTJSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- VFWQQZMRKFOGLE-ZLUOBGJFSA-N Ser-Ser-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O VFWQQZMRKFOGLE-ZLUOBGJFSA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- RXUOAOOZIWABBW-XGEHTFHBSA-N Ser-Thr-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RXUOAOOZIWABBW-XGEHTFHBSA-N 0.000 description 1
- VLMIUSLQONKLDV-HEIBUPTGSA-N Ser-Thr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VLMIUSLQONKLDV-HEIBUPTGSA-N 0.000 description 1
- VVKVHAOOUGNDPJ-SRVKXCTJSA-N Ser-Tyr-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VVKVHAOOUGNDPJ-SRVKXCTJSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- XDARBNMYXKUFOJ-GSSVUCPTSA-N Thr-Asp-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XDARBNMYXKUFOJ-GSSVUCPTSA-N 0.000 description 1
- YAAPRMFURSENOZ-KATARQTJSA-N Thr-Cys-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N)O YAAPRMFURSENOZ-KATARQTJSA-N 0.000 description 1
- BECPPKYKPSRKCP-ZDLURKLDSA-N Thr-Glu Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O BECPPKYKPSRKCP-ZDLURKLDSA-N 0.000 description 1
- XPNSAQMEAVSQRD-FBCQKBJTSA-N Thr-Gly-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)NCC(O)=O XPNSAQMEAVSQRD-FBCQKBJTSA-N 0.000 description 1
- YUOCMLNTUZAGNF-KLHWPWHYSA-N Thr-His-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N)O YUOCMLNTUZAGNF-KLHWPWHYSA-N 0.000 description 1
- NCXVJIQMWSGRHY-KXNHARMFSA-N Thr-Leu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O NCXVJIQMWSGRHY-KXNHARMFSA-N 0.000 description 1
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 1
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
- KRDSCBLRHORMRK-JXUBOQSCSA-N Thr-Lys-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O KRDSCBLRHORMRK-JXUBOQSCSA-N 0.000 description 1
- GUHLYMZJVXUIPO-RCWTZXSCSA-N Thr-Met-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O GUHLYMZJVXUIPO-RCWTZXSCSA-N 0.000 description 1
- MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 1
- SGAOHNPSEPVAFP-ZDLURKLDSA-N Thr-Ser-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SGAOHNPSEPVAFP-ZDLURKLDSA-N 0.000 description 1
- IEZVHOULSUULHD-XGEHTFHBSA-N Thr-Ser-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O IEZVHOULSUULHD-XGEHTFHBSA-N 0.000 description 1
- CSNBWOJOEOPYIJ-UVOCVTCTSA-N Thr-Thr-Lys Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O CSNBWOJOEOPYIJ-UVOCVTCTSA-N 0.000 description 1
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 1
- BJJRNAVDQGREGC-HOUAVDHOSA-N Thr-Trp-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O BJJRNAVDQGREGC-HOUAVDHOSA-N 0.000 description 1
- IJKNKFJZOJCKRR-GBALPHGKSA-N Thr-Trp-Ser Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 IJKNKFJZOJCKRR-GBALPHGKSA-N 0.000 description 1
- CKHWEVXPLJBEOZ-VQVTYTSYSA-N Thr-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O CKHWEVXPLJBEOZ-VQVTYTSYSA-N 0.000 description 1
- PWONLXBUSVIZPH-RHYQMDGZSA-N Thr-Val-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O PWONLXBUSVIZPH-RHYQMDGZSA-N 0.000 description 1
- VPRHDRKAPYZMHL-SZMVWBNQSA-N Trp-Leu-Glu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 VPRHDRKAPYZMHL-SZMVWBNQSA-N 0.000 description 1
- UJRIVCPPPMYCNA-HOCLYGCPSA-N Trp-Leu-Gly Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N UJRIVCPPPMYCNA-HOCLYGCPSA-N 0.000 description 1
- IQXWAJUIAQLZNX-IHPCNDPISA-N Trp-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N IQXWAJUIAQLZNX-IHPCNDPISA-N 0.000 description 1
- YLGQHMHKAASRGJ-WDSOQIARSA-N Trp-Leu-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N YLGQHMHKAASRGJ-WDSOQIARSA-N 0.000 description 1
- BVDHHLMIZFCAAU-BZSNNMDCSA-N Tyr-Cys-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O BVDHHLMIZFCAAU-BZSNNMDCSA-N 0.000 description 1
- HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 1
- IJUTXXAXQODRMW-KBPBESRZSA-N Tyr-Gly-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O IJUTXXAXQODRMW-KBPBESRZSA-N 0.000 description 1
- GULIUBBXCYPDJU-CQDKDKBSSA-N Tyr-Leu-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 GULIUBBXCYPDJU-CQDKDKBSSA-N 0.000 description 1
- CLEGSEJVGBYZBJ-MEYUZBJRSA-N Tyr-Thr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CLEGSEJVGBYZBJ-MEYUZBJRSA-N 0.000 description 1
- AOIZTZRWMSPPAY-KAOXEZKKSA-N Tyr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)O AOIZTZRWMSPPAY-KAOXEZKKSA-N 0.000 description 1
- ZYVAAYAOTVJBSS-GMVOTWDCSA-N Tyr-Trp-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(O)=O ZYVAAYAOTVJBSS-GMVOTWDCSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- YFOCMOVJBQDBCE-NRPADANISA-N Val-Ala-Glu Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N YFOCMOVJBQDBCE-NRPADANISA-N 0.000 description 1
- RUCNAYOMFXRIKJ-DCAQKATOSA-N Val-Ala-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN RUCNAYOMFXRIKJ-DCAQKATOSA-N 0.000 description 1
- KKHRWGYHBZORMQ-NHCYSSNCSA-N Val-Arg-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N KKHRWGYHBZORMQ-NHCYSSNCSA-N 0.000 description 1
- CVUDMNSZAIZFAE-TUAOUCFPSA-N Val-Arg-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N CVUDMNSZAIZFAE-TUAOUCFPSA-N 0.000 description 1
- CVUDMNSZAIZFAE-UHFFFAOYSA-N Val-Arg-Pro Natural products NC(N)=NCCCC(NC(=O)C(N)C(C)C)C(=O)N1CCCC1C(O)=O CVUDMNSZAIZFAE-UHFFFAOYSA-N 0.000 description 1
- VMRFIKXKOFNMHW-GUBZILKMSA-N Val-Arg-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N VMRFIKXKOFNMHW-GUBZILKMSA-N 0.000 description 1
- BYOHPUZJVXWHAE-BYULHYEWSA-N Val-Asn-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N BYOHPUZJVXWHAE-BYULHYEWSA-N 0.000 description 1
- LNYOXPDEIZJDEI-NHCYSSNCSA-N Val-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N LNYOXPDEIZJDEI-NHCYSSNCSA-N 0.000 description 1
- IDKGBVZGNTYYCC-QXEWZRGKSA-N Val-Asn-Pro Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(O)=O IDKGBVZGNTYYCC-QXEWZRGKSA-N 0.000 description 1
- DBOXBUDEAJVKRE-LSJOCFKGSA-N Val-Asn-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N DBOXBUDEAJVKRE-LSJOCFKGSA-N 0.000 description 1
- XQVRMLRMTAGSFJ-QXEWZRGKSA-N Val-Asp-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N XQVRMLRMTAGSFJ-QXEWZRGKSA-N 0.000 description 1
- TZVUSFMQWPWHON-NHCYSSNCSA-N Val-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N TZVUSFMQWPWHON-NHCYSSNCSA-N 0.000 description 1
- HIZMLPKDJAXDRG-FXQIFTODSA-N Val-Cys-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N HIZMLPKDJAXDRG-FXQIFTODSA-N 0.000 description 1
- RHYOAUJXSRWVJT-GVXVVHGQSA-N Val-His-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RHYOAUJXSRWVJT-GVXVVHGQSA-N 0.000 description 1
- CHWRZUGUMAMTFC-IHRRRGAJSA-N Val-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CNC=N1 CHWRZUGUMAMTFC-IHRRRGAJSA-N 0.000 description 1
- OJOMXGVLFKYDKP-QXEWZRGKSA-N Val-Met-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OJOMXGVLFKYDKP-QXEWZRGKSA-N 0.000 description 1
- HJSLDXZAZGFPDK-ULQDDVLXSA-N Val-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N HJSLDXZAZGFPDK-ULQDDVLXSA-N 0.000 description 1
- VCIYTVOBLZHFSC-XHSDSOJGSA-N Val-Phe-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N VCIYTVOBLZHFSC-XHSDSOJGSA-N 0.000 description 1
- DEGUERSKQBRZMZ-FXQIFTODSA-N Val-Ser-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DEGUERSKQBRZMZ-FXQIFTODSA-N 0.000 description 1
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 1
- QZKVWWIUSQGWMY-IHRRRGAJSA-N Val-Ser-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QZKVWWIUSQGWMY-IHRRRGAJSA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- MNSSBIHFEUUXNW-RCWTZXSCSA-N Val-Thr-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N MNSSBIHFEUUXNW-RCWTZXSCSA-N 0.000 description 1
- TVGWMCTYUFBXAP-QTKMDUPCSA-N Val-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N)O TVGWMCTYUFBXAP-QTKMDUPCSA-N 0.000 description 1
- UEXPMFIAZZHEAD-HSHDSVGOSA-N Val-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](C(C)C)N)O UEXPMFIAZZHEAD-HSHDSVGOSA-N 0.000 description 1
- YLBNZCJFSVJDRJ-KJEVXHAQSA-N Val-Thr-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O YLBNZCJFSVJDRJ-KJEVXHAQSA-N 0.000 description 1
- QPJSIBAOZBVELU-BPNCWPANSA-N Val-Tyr-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N QPJSIBAOZBVELU-BPNCWPANSA-N 0.000 description 1
- STTYIMSDIYISRG-UHFFFAOYSA-N Valyl-Serine Chemical compound CC(C)C(N)C(=O)NC(CO)C(O)=O STTYIMSDIYISRG-UHFFFAOYSA-N 0.000 description 1
- BKXQBXXALHYQKZ-NPGUAINNSA-N [3-[(2r)-2-(hexadecanoylamino)-3-methoxy-3-oxopropyl]sulfanyl-2-hexadecanoyloxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H](C(=O)OC)CSCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC BKXQBXXALHYQKZ-NPGUAINNSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 108010045350 alanyl-tyrosyl-alanine Proteins 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003229 cytophilic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 108010009297 diglycyl-histidine Proteins 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940124582 fever medication Drugs 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 1
- 108010072405 glycyl-aspartyl-glycine Proteins 0.000 description 1
- 108010081985 glycyl-cystinyl-aspartic acid Proteins 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010025801 glycyl-prolyl-arginine Proteins 0.000 description 1
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 1
- 108010045126 glycyl-tyrosyl-glycine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 108010015666 tryptophyl-leucyl-glutamic acid Proteins 0.000 description 1
- 108010084932 tryptophyl-proline Proteins 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 1
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Description
- l -
SYNTHETIC PEPTIDE BASED IMMUNOGENS FOR THE TREATMENT OF ALLERGY
CROSS REFERENCE TO RELATED APPLICATION
This is a continuation-in-part application of pending Application Serial No. 08/218,461 filed March 2.8, 1994 which is a continuation of pending application Serial No. 08/060,798 filed May 10, 1993 which is a continuation- in-part of pending application Serial No. 07/847,745, filed March 6, 1992, now abandoned, which was a continuation-in-part of application Serial No. 07/637,364, filed January 4, 1991, now abandoned.
FIELD OF THE INVENTION
The present invention relates to the use of a composition of a synthetic peptide, in a linear or radially branching multimeric form, as an immunogen for eliciting the production in healthy mammals, including humans, of high titer antibodies to the effector site on the CH4 domain of the e-chain of the human IgE heavy- chain, and to the use of the composition as a vaccine to provide an immunotherapy for the treatment of allergy.
BACKGROUND OF THE INVENTION
Immunotherapy for the prevention of IgE-mediated allergic responses, such as asthma and hay fever, as known and practiced since early in this century, has been by desensitization or hyposensitization, wherein a gradually increasing amount of an allergen is given to a patient to reduce the effects of subsequent exposure to that allergen'11. Limitations to such an allergen-based immunotherapy include difficulties in identifying the allergen involved and, if an allergen is identified, the adverse reactions frequently caused by the use of the identified allergen'2' .
Other treatments for the relief of allergies employ drugs to block the cascade of cellular events that
is responsible for allergic reactions. These drugs include anti-histamines, decongestants, β2 agonists, and corticosteroids. Anti-histamines, decongestants, and β2 agonists act on events downstream of IgE in the allergic cascade, making them palliative remedies which address only the allergy symptoms. Preventative treatments must act on cellular events closer to the initiation of IgE- mediated allergic reactions. These palliatives provide relief that is short term and partial. Moreover, the relief of symptoms is frequently accompanied by adverse side effects, e.g. anti-histamines may cause restlessness or drowsiness, and β2 agonists have sometimes been associated with increased morbidity in asthmatic patients.
Corticosteroids are powerful immunosuppressants and are highly efficacious for the treatment of allergic symptoms. However, they stimulate adverse hormonal activities and may cause an undesirably broad immunosuppression.
To avoid the shortcomings of the known therapeutic drugs, it would be more desirable to prevent allergic responses by selective suppression targeted to IgE. This may be accomplished either by suppressing IgE synthesis, such as is achieved by the inconvenient desensitization method; or by blocking the process by which IgE-allergen complexes stimulate the degranulation of mast cells and basophils with the concomitant release of the chemical mediators of hypersensitivity.
At a more fundamental level, Stanworth et al.'3"7' and others'8"131 have used synthetic IgE e-chain peptides and the corresponding antibodies to study the role of cytophilic peptides in cell signaling processes, in an attempt to elucidate the molecular basis for the immunological triggering of mast cells and basophils.
Among the many IgE peptides studied over the past two decades (Table 1) , a potential effector site within the Fc CH4 domain of the human e-chain (Lys497-
Phe506, shown in Table 2 by double underlining) was the decapeptide. It was synthesized and used for structure/activity studies'3'. This IgE CH4 domain-derived decapeptide was found to be capable of activating dose- dependent histamine release from isolated rat peritoneal mast cells in a non-cytolytic manner resembling the IgE- mediated mast cell triggering process'4'. Precise structural requirements for this peptide effector site were deduced through structure-activity studies using multiple synthetic analogues of the e-chain decapeptide(3'4,5' .
Anti-IgE CH4 peptide antibodies derived from immunizations with e chain-related "peptide-carrier protein conjugates" were also used for structure action studies on the degranulation of IgE-sensitized cells, by observing inhibitory activities'5,11,12' .
The feasibility of using a peptide based vaccine to provide immunotherapy to patients with IgE-mediated sensitivities has been suggested by Stanworth et al.'14,15). He used the previously identified e-chain decapeptide with a sequence of Lys-Thr-Lys-Gly-Ser-Gly-Phe-Phe-Val-Phe- NH2 <3) (SEQ ID NO:l) conjugated to a "carrier protein", such as keyhole limpet hemocyanin (KLH) or the purified protein derivative (PPD) of tuberculin, and found that the "peptide-carrier protein" conjugates elicited decapeptide- specific antibodies. For example, a rabbit anti-peptide serum, selected on the basis of its better-than-average anti-peptide titer, reduced the decapeptide-induced histamine release from rat peritoneal mast cells in a titer-dependent fashion. This inhibitory activity was further confirmed by in vivo tests in a rat passive cutaneous anaphylaxis (PCA) model system. The effect of this rabbit anti-peptide serum on anaphylaxis was assessed, by measurement of the area of blueing and by an estimate of color intensity when given to rats which had been previously sensitized by multiple allergen
application prior to anaphylactic challenge with the allergen.
In the same study, results obtained in rats using immunogens containing such "decapeptide-protein carrier conjugates" gave preliminary indications of feasibility for their use as a vaccine for the treatment of allergy.
However, this strategy has met with considerable difficulties. The major deficiencies of this prototype "decapeptide-protein carrier conjugate" vaccine include a less-than-optimal immune stimulatory capability and manufacturing difficulties stemming from the poorly defined composition of the carrier protein and the non- uniformity of the conjugation reaction. It has also been found that the resultant antisera raised by such peptide-protein conjugates frequently contain more antibodies directed at the epitopes on the protein carrier, e.g. Keyhole Limpet Hemocyanin (KLH) , than to the target-peptide'51.
o N>
O Ui IΛ
TABLE 1 IgE HEAVY CHAIN PEPTIDES USED IN STRUCTURE-ACTIVITY STUDIES
Amino Acid Res. Nos. and Peptide Sequence Doma n Structure-Activity Studies References
Hu e 497-506 CH4 Involved in non-antigen receptors in Stanworth, Hoi. Immunol.. 21:1183-1190. 1984(4) RTKGSGFFVF mast cell signalling processes Stanworth and Burt. Hoi. Immunol.. 23:1231-1235. 1986(5)
Hu e 301-376 CH2/CH3 Blocking of passive sensitization of Helm et al., PNAS, 86:9465-9469, 1989(13) human mast cells and basophils
Hu e 363-376 CH3 Not essential for binding of the ibid. peptide to Fc f-chain receptor I.
Hu 6367-376 CH3 Binding to the low affinity IgE Chretien et al.. J. Immunol.. 141:3128-3134. 1988(11) receptor (CD23)
E. col -derived human Fee fragment CH2/CH3/CH4 Expression in E. coli and comparison enten et al., PNAS 81:2955-2959, 1984(12) to cell- binding activity of native human IgE myeloma. Recombinant Fc had 20% of native binding activity.
E. coli-derived human Fee fragment CH2/CH3/CH4 Monomeric form was inactive. The Fc- Coleman et al.. Eur. J. Immunol.. 15:966-969. 1985(13) like dimeric form displayed only 'A of the cell-binding activity of native IgE.
Rat e CH3/CH4 Inhibiting binding of rat IgE to mast Burt and Stanworth. Eur. J. Immunol.. 17:437-440.
414-428(p129)* cells by 20-50% at concentrations 1987(9)
459-472(p124) between 10"4-10"5M.
491-503(p128) *Even the most active peptide(p129)
542-557(p123) was found 1000-times less active than the active rat IgE.
378-396(p130) CH3/CH4 No inhibition 522-535(p122) 560-571(p131)
It is known to those of skill in the art, small peptides are poor immunogens. To make small peptides immunogenic, they are usually joined to large carrier proteins by chemical conjugation or by gene fusion. These processes, however, generally produce unpredictable conformational changes in a peptide. Further, the immune response is frequently misdirected to the immunodominant carrier. Consequently, the development of a potent vaccine to provide long-lasting relief from allergies awaits further immunogen design. in Table 2, the amino acid sequences for the CH2 to CH4 domains of rat IgE ε-chain(16) and mouse e-chain(17) are aligned with the amino acid sequence for human e-chain(18) (SEQ ID NOS:2-4) to provide a guide for IgE- related peptide fragments previously reported. It is to be noted that in human IgE e heavy chain, L next to Q at position 252 is not present in the original IgE myeloma ND sequence. Gaps, indicated by dashes, have been introduced to maximize ho ology. Matches of homologous residue positions are boxed. The positions on the e sequences which have been studied for structural activity (Table 1) are underlined in Table 2. The structurally active IgE CH4 decapeptide sequence in the human IgE CH4 domain is double underlined (SEQ ID NO:l) . The amino acid code used in the Table is: A, alanine; R, arginine; N, asparagine; D, aspartic acid; C, cysteine; Q, glutamine;
E, glutamic acid; G, glycine; H, histidine; I, isoleucine; L, leucine; K, lysine; M, methionine; F, phenylalanine; P, proline; S, serine; T, threonine; W, tryptophan; Y, tyrosine; V, valine.
t o O Ul tΛ
Table 2
Sequence
224 249 273
Human € V C S R D F T P P T V K I L Q S S - C D G G G H F P P T I Q L (L) C L V S G Y T P G T I N I T W E D - G Q VM D V D L S T A S T T Q E G E (SEQ ID
N0:2) Rat e (SEQ ID
N0:3) Mouse € R P V T H S L S P P W S Y S I H R C D P N A H S T I Q L F I Y H I L H D V S V S W L D R E I T D T L A Q T V L I K E E G (SEQ ID
N0:4)
298 323 <--CH2] tCH3--> 348
O
Human f L A S T Q S Q L T L S Q K H W L S D R T Y T C Q V T Y Q G H T F Q D S T K K C A D S N P R G V S A Y L S R P S P F D L F I R K S P T I T
Rat e N L N I T Q Q Q W M S E S T F T C K V T S Q G E N Y W A H T R R C S D D E P R G V I T Y L I P P S P L D L Y E N G T P K L T
Mouse ε L A S T C S K L N I T E Q Q W M S E S T F T C R V T S Q G C D Y L A H T R R C P D H E P R G A I T Y L I P P S P L D L Y Q N G A P K L T
372 395 421
Human € C L V L O L A P S K G T V II L T W S R A S G K P - V N N S T R K E E K Q R - N G T L T V T S T P V G T R D W I E G E T Y Q C R V T H P H
Rat e C L V L D L E S E I T V T W R E K K S I G S A S Q R K H H N A T T S I T S I L P V A K D W I E G E G Y Q C R V D H P H
Mouse € C L V V D L E S E N V N V T W N Q E K K T SV SA S Q W Y K H H M A T T S I T S I L P V A K D W I E GIY G Y Q C I V D R P D
UJ to o o LΛ
Table 2 (cont'd)
<--CH3][CH4--> 446
Human ε R A L M R S T T K T S R A A P E V Y A F A T P E U P G S R D K R T L A C L I Q N F M P E D I S V Q W L H N E V Q L P D A R H S
Rat e F P K P I V R S I T K A L R S A P E V Y V F L P P E - E E E K N K R T L T C L I Q N F F P E
Mouse € F P K P I V R S I T L P Q V S Q R S A P E V Y V F P P P E - E E S E D K R T L T C L I Q N F F P E D I S V Q W L G D G K L I S N S Q H S
495 517 542 547
Human e T T Q P R K T K G S - - G F F V F S R L E V T R A E u Q E K D E F I C R A V H E A A S P S Q T V Q R A V S V N P G K
Rat e
Mouse ε T T T P L K S N G N Q G F F I F S R L E V A K T L w T Q R K Q - F T C Q V I H E A L Q K P R
365
10
LIST OF REFERENCES
I. Noon L. "Prophylactic inoculation against hay fever." Lancet, i:1572-1573 (1911) .
2. World Health Organization and International Union of Immunological Societies Working Group Report : Current status of allergen immunotherapy. Lancet. i:259-261 (1989) . 3. Stanworth, Kings, Roy, et al . Biochem. J. , 180:665- 668 (1979) . 4. Stanworth. Mol. Immunol . , 21:1183-1190 (1984) .
5. Stanworth, and Burt. Mol. Immunol. , 23:1231-1235
(1986) .
6. Burt, and Stanworth. Eur. J. Immunol . , 17:437-440
(1987) . 7. Stanworth. Mol■ Immunol.. 25:1213-1215 (1988) .
8. Hamburger. Science, 189:389-390 (1975) .
9. Kenten, Helm, Ishizaka, et al . Proc. Natl. Acad Sci., USA, 81:2955-2956 (1984) .
10. Coleman, Helm, Stanworth, and Gould. Eur. J. Immunol.. 15:966-969 (1985) .
II. Chretien, Helm, Marsh, et al. J. Immunol. , 141:3128- 3134 (1988) .
12. Robertson, and Lin. Mol . Immunol. , 25:103-113 (1988) .
13. Helm, Kebo, Vercelli, et al. Proc. Natl. Acad. Sci., USA 86:9465-9469 (1989) .
14. Stanworth, Jones, Lewin, and Nayyar. Allergy treatment with a peptide vaccine. Lancet, 336:1279- 1281 (1990) .
15. Stanworth, Lewin Nayyar, and Jones. Immunoreactive peptides and antibodies and their use in anti-allergy treatment. EPO 403 312 Al (1990) .
16. Kindsroger et al. , DNA 1:335-343 (1982) .
17. Ishida et al. , EMBO 1:1117-1123 (1982) .
18. Dorrington and Bennich, Immunol. Rev. , 41:3-25 (1978> •
19. Brett et al. Eur. J. Immunol. , 23:1608-1614 (1993) .
20. Weismuller et al. , Int. J. Peptide Res., 40:255-260
(1992) .
21. Celis et al. , J. Immunol. , 140:1808-1815 (1988) . 22. Demotz et al. , J. Immunol. , 142:394-402 (1989) .
23. Chong et al. , Infect. Immun. , 60:4640-4647 (1992) .
24. Grant ed. , Synthetic Peptides: A User's Guide, W.H.Freeman & Co., New York, NY, (1992) pp. 382.
25. O'Hagan et al. , Vaccine, 9:768-771 (1991) . 26. Eldridge et al., Molec. Immunol. , 28:287-294 (1991) . 27. MacGlashan et al., J. Immunol. , 136:2231-2239 (1986)
OBJECTS OF THE INVENTION It is, an objective of the present invention to employ a group of IgE e-chain based peptide immunogens chemically synthesized in either a radially branching form or a linear T helper epitope containing form, to elicit high titer antibodies to the decapeptide effector site of the CH4 domain of the human e-chain, when introduced to mammals, including humans.
Another objective is to design optimal peptide immunogens, with specific amino acid sequences taken from the human IgE heavy chain CH4 domain (IgE CH4) attached to peptides containing promiscuous human helper T cell epitopes in a specific orientation which, when introduced into mammals, including humans, will stimulate production of high titers of efficacious antibodies to the effector site on human IgE CH4. These antibodies should inhibit mast cell activation, reduce the release of chemical mediators such as histamines that are responsible for allergy symptoms, depress IgE-mediated passive cutaneous anaphylaxis (PCA) reaction, and suppress allergen-induced IgE production by B lymphocytes.
A further objective is to develop an effective IgE e-chain peptide-based vaccine, employing compositions containing such branching multimeric or linear immunogens, to provide immunotherapy for the treatment of allergic reactions.
SUMMARY OF THE INVENTION According to the present invention, peptide immunogens are made by solid phase synthesis. The peptide immunogens comprise a series of radially branched multimeric peptides containing a ten amino acid IgE CH4 peptide (SEQ ID NO:l) , or an immunogenic analog thereof; a series of multimeric branched peptides containing the IgE CH4 peptide (SEQ ID NO:l) or an immunogenic analog thereof together with a helper T-cell epitope (Th epitope) ; and a
series of linear monomeric peptides containing the IgE CH4 peptide (SEQ ID N0:1) or an immunogenic analog thereof together with a portion of a helper T-cell epitope (Th epitope) . The IgE CH4 peptide is taken from the Fc region of the IgE heavy chain, i.e. e-chain CH4 domain (IgE CH4) . Of the three series of peptide immunogens, the linear peptides are preferred. Compositions containing these peptides are used to immunize healthy mammals, e.g. guinea pigs, rats, and humans, to elicit the production of high titer antisera specific for the IgE CH4 effector site (SEQ ID N0:1) and free of irrelevant antibodies.
According to the present invention, vaccines containing the synthetic peptides as the key immunogen may also be prepared with an effective amount of a multimeric- branching peptide or a linear peptide in the presence of a proper adjuvant and/or delivery vehicle. It is expected that such vaccine compositions will elicit a more focused anti-IgE peptide response than those of the peptide- carrier protein conjugates currently used by Stanworth et al.(1 ), thus providing a better immunotherapy for the treatment of allergy.
DETAILED DESCRIPTION OF THE INVENTION This invention is directed to the use of a novel group of peptide-based immunogens for the generation of high titer antibodies to an effector site on the CH4 domain of human IgE e heavy chain (SEQ ID NO:l) in healthy mammals, including humans, for the treatment of IgE- mediated allergic diseases.
It is generally accepted that allergy symptoms, the immediate result of IgE-dependent hypersensitivities, are caused by chemical mediators released by mast cells and basophils. The release is triggered when a mast cell or basophil that has been sensitized with surface-bound IgE binds to an allergen for which the surface-bound IgE is specific. The triggering is actuated by the binding of
the allergen to the Fab' portion of the surf ce-bound IgE in an antigen-antibody type interaction. The allergen/antibody binding crosslinks the bivalent surface- bound IgE and induces a conformational change in the distal Fc region of IgE, the region of IgE in direct contact with a high affinity Fc receptor on the cell surface. By a mechanism as yet not precisely understood, the conformational change activates the cell-IgE-allergen complex with the resultant release of mediators, including histamine, by the cell. Effector site(s) on IgE are believed to participate in the triggering event. The presence of specific anti-IgE antibodies directed against such "effector sites", through either active or passive immunization, may lead to inhibition of the cell activation process in hosts suffering from allergic reactions by interfering with the interaction between the IgE "effector sites" and the cell surface.
Such interventions through the use of specific anti-IgE antibodies, i.e. a kind of immunotherapy, can be achieved either passively, through prophylactic treatment with specific "site-directed" antibodies to IgE, or, more preferably, actively, by providing the host with a vaccine comprised of site-directed peptide immunogens, to elicit the production by the host of its own site-directed anti- IgE antibodies. It is believed that active immunization will provide a more effective and longer lasting protection.
Among the sites from the Fc region of circulating IgE that have been studied for functional activity, a region on the CH4 domain of the IgE molecule (Lys497-Phe506) has been identified as a conformational effector involved in the triggering of mast cells and basophils'3"8,14' . See Table 1 and the areas underlined in Table 2. A decapeptide derived from this site with the sequence Lys-Thr-Lys-Gly-Ser-Gly-Phe-Phe-Val-Phe-NH2 (SEQ
ID N0:1) was found to approximate the conformation of this effector site. . This is evidenced by the ability of the decapeptide to elicit dose-dependent histamine release from rat mast cells in a manner resembling the immunological triggering process(4).
Stanworth et al.<14,15) demonstrated the feasibility of providing immunotherapy to patients with IgE-mediated allergic reactions through the use of experimental vaccines by using the IgE CH4 decapeptide (SEQ ID N0:1) coupled to a carrier protein, keyhole limpet hemocyanin (KLH) as an immunogen. Animal immune sera obtained from such immunizations were found by Stanworth et al.(1 ,15) to moderately reduce the decapeptide-induced histamine release from rat peritoneal mast cells in a titer-dependent fashion. Inhibitory activity by the immune sera generated was further confirmed by in vivo passive cutaneous anaphylaxis (PCA) tests under conditions of multiple allergen application.
A major deficiency of the prototype "IgE CH4 peptide" vaccine developed by Stanworth et al is its weak immunogenicity, a problem inherently associated with almost all self-antigens.
In the present invention, specific immunogens are provided wherein synthetic immune stimulatory elements are linked to the CH4 decapeptide of IgE (SEQ ID NO:l) in a specific orientation such that potent antibodies directed to this effector site on IgE can be broadly generated in a genetically diverse host population. In turn, these antibodies block the stimulatory action of IgE on mast cells and basophils, thus resulting in an effective treatment to prevent IgE-mediated allergic diseases.
The peptide immunogens of the present invention are capable of eliciting antibodies with serological cross-reactivity with the target amino acid sequence of
the Fc region of IgE (SEQ ID N0:1) while being substantially incapable of mediating non-cytolytic histamine release.
The initial dose, e.g. 0.2-2.5 mg; preferably 1 mg, of immunogen is to be administered by injection, preferably intramuscular, followed by repeat (booster) doses. Dosage will depend on the age, weight and general health of the patient as is well known in the therapeutic arts. While there is no particular limitation to the species of mammals suitable for the production of antibodies, it is generally preferred to use mice, rabbits, guinea pigs, pigs, goats, rats or sheep, etc. as the hosts. For active immunization, the term "immunogen" referred to herein relates to synthetic peptides which are capable of■ inducing antibodies against the IgE CH4 decapeptide (SEQ ID N0:1), which antibodies lead to the suppression of IgE-mediated basophil and mast cell degranulation. The immunogen of this invention included multimeric peptides or its analogs with a branching lysyl core matrix structure.
These branched multimeric peptides have the capability of independently eliciting an immune response in a host animal. The analogs of IgE CH4 decapeptide (SEQ ID N0:1) include the synthetic peptide analogs described by Stanworth et al.(3,4,5), which are incorporated herein by reference. To be suitable, the molecular weight of the immunogen should be higher than 5,000 and preferably be higher than 10,000. The repeating branch unit for the peptide should be equal to or higher than 4.
Bifunctional amino acids such as lysine followed by attachment to an amino acid with a preferably non- charged side chain, such as Gly or Ala, are useful in the making of the core matrix structure. By inserting an
amino acid in one additional coupling cycle in between two di-Boc-Lysine coupling cycles, the amino acid acts as a spacer in between the peptide branches to allow maximum freedom to attain the conformation necessary for optimal presentation.
The immunogen referred to in the present invention also included linear peptides which contain promiscuous helper T cell epitopes (Th epitopes) . These Th epitopes were covalently attached in a defined fashion to the decapeptide effector sequence (SEQ ID N0:1) , with or without a spacer, so as to be adjacent to the N terminus of the decapeptide, in order to evoke efficient antibody responses. The immunogen may also be comprised of an immune stimulatory sequence corresponding, for example, to a domain of an invasin protein from the bacteria Yersinia spp(19) . The invasin domain may also be attached through a spacer to a Th epitope.
The "immunogen" of the present invention minimizes the generation of irrelevant antibodies, thus eliciting a more focused immune response to the "target sequence", i.e., the desired IgE CH4 cross-reactivity (SEQ ID NO:l) , without producing undesirable side effects which may complicate the immunotherapy process for the treatment of allergy. However, when a short target sequence, such as the 10 amino acid IgE CH4 segment Lys-Thr-Lys-Gly-Ser-Gly- Phe-Phe-Val-Phe (SEQ ID N0:1), is used to design a carrier protein-free immunogen, one faces serious challenges. A short peptide antigen, is usually a T cell-dependent antigen, i.e. the presence of a T helper epitope is required to render a short "target" peptide immunogenic. The short IgE CH4 decapeptide (SEQ ID NO:l) or an immunogenic analog thereof does not contain a T helper cell epitope. The branched multimeric and linear immunogens comprising the short IgE CH4 decapeptide are
designed herein to provide for artificially built-in functional helper T-cell epitopes.
The peptides immunogens of this invention are represented by the formula (A)n-(Th)ra-(B)0-(IgE CH4 peptide)p wherein
A is an amino acid, α-NH2, a fatty acid, a derivative of a fatty acid, or an invasin domain; B is an amino acid;
Th is a helper T cell epitope or an immune enhancing analog or segment thereof;
IgE CH4 peptide is Lys-Thr-Lys-Gly-Ser-Gly-Phe-
Phe-Val-Phe (SEQ ID NO:l) or an immunogenic analog thereof; n is from 1 to 10; m is from 1 to 4; o is from 0 to 10; and p is from 1 to 3. The peptide immunogens of the present invention comprise from about 20 to about 100 amino acid residues, preferably from about 20 to about 50 amino acid residues and more preferably from about 20 to about 35 amino acid residues. When A is an amino acid, it can be any non- naturally occurring or any naturally occurring amino acid. Non-naturally occurring amino acids include, but are not limited to, β-alanine, ornithine, norleucine, norvaline, hydroxyproline, thyroxine, γ-amino butyric acid, homoserine, citrulline and the like. Naturally-occurring amino acids include alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine. Moreover, when n is
greater than one, and two or more of the A groups are amino acids, then each amino acid is independently the same or different.
When A is a fatty acid, such as stearic acid or palmitic acid or a fatty acid derivative, such as a tripalmitoyl cysteine (Pam3Cys) group, it acts as an adjuvant by enhancing the immunostimulating properties of the Th epitope(20). When A is a fatty acid or its derivative it is usually located at the amino terminus of the peptide. Furthermore, when one of A is a fatty acid, there are 2 or 3 additional amino acid A moieties. The fatty acids useful in the invention have a hydrocarbon chain of 8 to 24 carbon atoms which may be saturated or unsaturated.
When A is an invasin domain, it is an immune stimulatory epitope from the invasin protein of a Yersinia species. This immune stimulatory property results from the capability of this invasin domain to interact with the βl integrin molecules present on T cells, particularly activated immune or memory T cells. The specific sequence for an invasin domain found to interact with the βl integrins has been described by Brett et al (19> . In a preferred embodiment, the invasin domain (Inv) for linkage to a promiscuous Th epitope has the sequence:
Thr-Ala-Lys-Ser-Lys-Lys-Phe-Pro-Ser-Tyr-Thr-Ala-
Thr-Tyr-Gln-Phe (SEQ ID NO: 25) or is an immune stimulatory analog thereof from the corresponding region in another Yersinia species invasin protein. Such analogs may contain substitutions, deletions or insertions to accommodate strain to strain variation, provided that the analogs retain immune stimulatory properties.
In one embodiment, n is 4 and A is α.-NH2, lysine, lysine and lysine in that order. In another embodiment n is 1 and A is α-NH2. In yet another
embodiment, n is 4 and A is o.-NH2, an invasin domain (Inv) , glycine and glycine in that order.
B comprises naturally occurring or the non- naturally occurring amino acids as described above. Each B may be independently the same or different. When B is lysine, a branched polymer can be formed. For example, if o is 7 and all seven B groups are lysine then a branching K core (K4K2K) is formed when the peptide synthesis is conducted without protecting the lysyl side chain e-amino group. Peptides with a K core have eight branch arms, with each branch arm being identical and represented as 11 (A)n- (Th)m-M or "(IgE CH4 peptide with built-in-Th) -" . In addition, the amino acids of B can form a flexible hinge, or spacer, to enhance the immune response to the Th epitope and IgE CH4 decapeptide or an analog thereof. Examples of sequences encoding flexible hinges can be found in the immunoglobulin heavy chain hinge region. Flexible hinge sequences are often proline rich. One particularly useful flexible hinge is provided by the sequence Pro-Pro-Xaa-Pro-Xaa-Pro (SEQ ID NO:24) , where Xaa is any amino acid, preferably aspartic acid. Immunogenicity can also be improved through the addition of spacer residues (e.g. Gly-Gly) between the promiscuous Th epitope and the IgE CH4 decapeptide or an analog thereof. In addition to physically separating the Th epitope from the B cell epitope (i.e., the IgE CH4 decapeptide site or an analog thereof) , the glycine residues can disrupt any artifactual secondary structures created by the joining of the Th epitope with the IgE CH4 decapeptide (SEQ ID N0:1) or an analog thereof and thereby eliminate interference between the T and/or B cell responses. Thus, the conformational separation between the helper cell and the antibody eliciting domains permits more efficient interactions between the presented immunogen and the appropriate Th and B cells.
Th is a Th epitope comprising natural or non- natural amino acids. A Th epitope may consist of a continuous or discontinuous epitope; not every amino acid of Th is necessarily part of the epitope. Th epitopes, including analogs and segments thereof, to be suitable for the present invention are capable of enhancing or stimulating an immune response to the IgE CH4 decapeptide (SEQ ID NO:l) or an analog thereof. Th epitopes that are immunodominant and promiscuous are highly and broadly reactive in animal and human populations with widely divergent MHC types'21"23'. The Th domain suitable for the present invention has from about 10 to about 50 amino acids and preferably from about 10 to about 30 amino acids. When multiple Th epitopes are present (i.e. m ≥ 2) , then each Th epitope may be independently the same or different.
Th epitope analogs include substitutions, additions, deletions and insertions of from one to about 10 amino acid residues in the Th epitope. Th segments are contiguous portions of a Th epitope that are sufficient to enhance or stimulate an immune response to the IgE CH4 decapeptide (SEQ ID NO:l) or an analog thereof.
Th epitopes of the present invention include hepatitis B surface and core antigen helper T cell epitopes (HBsTh and HBcTh) , pertussis toxin helper T cell epitopes (PT Th) , tetanus toxin helper T cell epitopes (TT Th) , measles virus F protein helper T cell epitopes (MVF Th) , Chlamydia trachomatis major outer membrane protein helper T cell epitopes. (CT Th) , diphtheria toxin helper T cell epitopes (DT Th) , Plasmodium falciparum circumsporozoite helper T cell epitopes (PF Th) , Schistosoma mansoni triose phosphate isomerase helper T cell epitopes (SM Th) , Escherichia coli TraT helper T cell epitopes (TraT Th) and immune-enhancing analogs and segments of any of these Th epitopes. Examples of Th
epitope sequences are provided below:
HBS Th: Phe-Phe-Leu-Leu-Thr-Arg-Ile-Leu-Thr-Ile-Pro-Gln-
Ser-Leu-Asp (SEQ ID NO: 5)
PTi Th: Lys-Lys-Leu-Arg-Arg-Leu-Leu-Tyr-Met-Ile-Tyr-Met-
Ser-Gly-Leu-Ala-Val-Arg-Val-His-Val-Ser-Lys-Glu- Glu-Gln-Tyr-Tyr-Asp-Tyr (SEQ ID NO: 6)
TTi Th: Lys-Lys-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-
Gly-Ile-Thr-Glu-Leu (SEQ ID NO: 7)
TT2 Th: Lys-Lys-Phe-Asn-Asn-Phe-Thr-Val-Ser-Phe-Trp-Leu-
Arg-Val-Pro-Lys-Val-Ser-Ala-Ser-His-Leu
(SEQ ID NO: 8)
PT1A Th: Tyr-Met-Ser-Gly-Leu-Ala-Val-Arg-Val-His-Val-Ser- Lys-Glu-Glu (SEQ ID NO: 9)
TT3 Th: Tyr-Asp-Pro-Asn-Tyr-Leu-Arg-Thr-Asp-Ser-Asp-Lys-
Asp-Arg-Phe-Leu-Gln-Thr-Met-Val-Lys-Leu-Phe-Asn- Arg-Ile-Lys (SEQ ID NO:10)
PT. Th: Gly-Ala-Tyr-Ala-Arg-Cys-Pro-Asn-Gly-Thr-Arg-Ala-
Leu-Thr-Val-Ala-Glu-Leu-Arg-Gly-Asn-Ala-Glu-Leu
(SEQ ID NO: 11)
MVF1 Th: Ser-Glu-Ile-Lys-Gly-Val-Ile-Val-His-Arg-Leu-Glu- Gly (SEQ ID NO: 12) and Leu-Ser-Glu-Ile-Lys-Gly-Val-Ile-Val-His-Arg-Leu- Glu-Gly-Val (SEQ ID NO: 61)
HBC Th: Val-Ser-Phe-Gly-Val-Trp-Ile-Arg-Thr-Pro-Pro-Ala-
Tyr-Arg-Pro-Pro-Asn-Ala-Pro-Ile-Leu
(SEQ ID NO: 14)
MVF2 Th: Gly-Ile-Leu-Glu-Ser-Arg-Gly-Ile-Lys-Ala-Arg-Ile- Thr-His-Val-Asp-Thr-Glu-Ser-Tyr (SEQ ID NO: 26)
TT4 Th: Trp-Val-Arg-Asp-Ile-Ile-Asp-Asp-Phe-Thr-Asn-Glu-
Ser-Ser-Gln-Lys-Thr (SEQ ID NO: 27)
TT5 Th: Asp-Val-Ser-Thr-Ile-Val-Pro-Tyr-Ile-Gly-Pro-Ala- Leu-Asn-His-Val (SEQ ID NO: 28)
CT Th: Ala-Leu-Asn-Ile-Trp-Asp-Arg-Phe-Asp-Val-Phe-Cys-
Thr-Leu-Gly-Ala-Thr-Thr-Gly-Tyr-Leu-Lys-Gly-Asn- Ser (SEQ ID NO: 29)
DTX Th: Asp-Ser-Glu-Thr-Ala-Asp-Asn-Leu-Glu-Lys-Thr-Val-
Ala-Ala-Leu-Ser-Ile-Leu-Pro-Gly-Ile-Gly-Cys
(SEQ ID NO: 30)
DT2 Th: Glu-Glu-Ile-Val-Ala-Gln-Ser-Ile-Ala-Leu-Ser-Ser-
Leu-Met-Val-Ala-Gln-Ala-Ile-Pro-Leu-Val-Gly-Glu- Leu-Val-Asp-Ile-Gly-Phe-Ala-Ala-Thr-Asn-Phe-Val- Glu-Ser-Cys (SEQ ID NO:31)
PF Th: Asp-Ile-Glu-Lys-Lys-Ile-Ala-Lys-Met-Glu-Lys-Ala-
Ser-Ser-Val-Phe-Asn-Val-Val-Asn-Ser
(SEQ ID NO: 32)
SM Th: Lys-Trp-Phe-Lys-Thr-Asn-Ala-Pro-Asn-Gly-Val-Asp-
Glu-Lys-Ile-Arg-Ile (SEQ ID NO: 33)
TraTx Th: Gly-Leu-Gln-Gly-Lys-Ile-Ala-Asp-Ala-Val-Lys-Ala- Lys-Gly (SEQ ID NO: 34)
TraT2 Th: Gly-Leu-Ala-Ala-Gly-Leu-Val-Gly-Met-Ala-Ala-Asp- Ala-Met-Val-Glu-Asp-Val-Asn (SEQ ID NO: 35)
TraT3 Th: Ser-Thr-Glu-Thr-Gly-Asn-Gln-His-His-Tyr-Gln-Thr- Arg-Val-Val-Ser-Asn-Ala-Asn-Lys (SEQ ID NO.-36)
Preferably, the Th epitope is HBS Th, P11 Th, PT2 Th, TTX Th, TT3 Th, or MVF1 Th.
In the monomeric linear peptides of this invention, as described by the Formula (A)n- (Th)m- (B)0- (IgE CH4 peptide) , the Th epitope is covalently attached through spacer B to the N terminus of the IgE CH4 decapeptide (SEQ ID NO:l) . The IgE CH4 peptide is Lys- Thr-Lys-Gly-Ser-Gly-Phe-Phe-Val-Phe (SEQ ID NO:l) , a decapeptide. The IgE CH4 peptide may be replaced by an immunogenic analog. The immunogenic analogs thereof may contain a substitution, addition, deletion, or insertion of from one to about four amino acid residues provided that the analog is capable of eliciting an immune response crossreactive with the IgE CH4 decapeptide (SEQ ID NO:l) . The substitutions, additions, and insertions may be made with natural or non-natural amino acids as defined herein. Immunogenic analogs of the IgE CH4 peptide (SEQ NO:l) have been identified by Stanworth et al.(3,4,5) and are incorporated herein by reference.
Accordingly, preferred peptide immunogens of this invention are monomeric peptides containing IgE CH4 decapeptide (SEQ ID NO:l) or an immunogenic analog thereof and Th. More specifically, preferred peptide immunogens are those linear constructs containing IgE CH4 (SEQ ID NO:l) or an immunogenic analog thereof; a spacer (e.g Gly- Gly) ; a Th epitope selected from the group consisting HBS Th, PTi Th, PT2 Th, TTX Th, TT3 Th, and MVF1 Th (SEQ ID NOS:5, 6,11,7,10, 61, respectively) ; and optionally the Inv domain (SEQ ID NO:25) . Preferred peptide immunogen compositions include, for example, Peptide Nos. 19-23 and 28 (Tables 5 and 6, SEQ ID NOS:51-55, 62) .
The peptide immunogens of this invention may be made by chemical synthesis well known to the ordinarily skilled artisan. See, for example, Grant, ed. Synthetic Peptides'24' . Hence, peptide immunogens may be synthesized using the automated Merrifield techniques of solid phase synthesis with the o.-NH2 protected by either t-Boc or F- moc chemistry using side chain protected amino acids on, for example, an Applied Biosystems Peptide Synthesizer Model 430A or 431. To synthesize a K core moiety on which to synthesize peptide branches, Di-α, e (t-Boc) lysine residues are used in place of t-Boc lysine with a 2,4- dichlorobenzyl protecting e-amino group.
When A is a fatty acid, it may be added easily to the N-terminus of the resin bound peptide by the well known carbodiimide method. To add Pam3Cys, the lipoamino acid S- [2,3-Bis (palmitoyloxy) - (2R) -propyl-N-palmitoyl- (R) - cysteine (Pam3Cys) is chemically synthesized. Pam3Cys may then be coupled to the N terminus of a peptide by solid- phase synthesis using Pam3Cys-OH in the final coupling step to link the lipoamino acid to a resin-bound peptide chain.
To improve the solubility of the final coupled lipopeptide product, the solid-phase peptide can be elongated with additional serine and lysine residues at the N-terminus.
After complete assembly of the desired peptide immunogen, the resin is treated according to standard procedures to cleave the peptide from the resin and deblock the functional groups on the amino acid side chains. The free peptide is purified by HPLC and characterized biochemically, for example, by amino acid analysis or by sequencing. Purification and characterization methods for peptides are well known to one of ordinary skill in the art.
Other chemical means to generate linear Th-IgE
CH4 decapeptide constructs of the invention include the ligation of the haloacetylated and the cysteinyl peptide through the formation of a "thioether" linkage. For example, cysteine can be added to the C terminus of a Th- containing peptide and the thiol group of cysteine is used to form a covalent bond to an electrophilic group such as an Nα chloroacetyl-modified or a maleimide-derivatized - or e-NH2 group of a lysine residue that is attached to the N-terminus of the IgE CH4 decapeptide (ID SEQ N0:1) or an immunogenic analog thereof.
The subject peptides can also be polymerized. Polymerization can be accomplished for example by reaction between glutaraldehyde and the -NH2 groups of the lysine residues using routine methodology. The linear "A-Th- spacer-IgECH4" peptide constructs (e.g., Peptide Nos. 19- 23 and 28, SEQ ID NOS:51-55 and 62) may also be polymerized -or co-polymerized by utilization of an additional cysteine added to the N-terminus of the linear "A-Th-spacer-IgECH4" construct. The thiol group of the N- terminal cys.teine may be used for the formation of a "thioether" bond with a halochloroacetyl-modified or a maleimide-derivatized cn- or e-NH2 group of a lysine residue that is attached to the N-terminus of a branched poly-lysyl core molecule (e.g., K2K, K4K2K, K8K4K2K) .
Alternatively, the longer linear peptide immunogens may be synthesized by well known recombinant DNA techniques. Any standard manual on DNA technology provides detailed protocols to produce the peptides of the invention. To construct a gene encoding a peptide of this invention, the amino acid sequence is reverse translated into a nucleic acid sequence, and preferably using optimized codon usage for the organism in which the gene will be expressed. Next, a synthetic gene is made, typically by synthesizing overlapping oligonucleotides which encode the peptide and any regulatory elements, if
necessary. The synthetic gene is inserted in a suitable cloning vector and recombinants are obtained and characterized. The peptide is then expressed under suitable conditions appropriate for the selected expression system and host. The peptide is purified and characterized by standard methods.
The efficacy of the peptide immunogen of the present invention may be established by injecting the immunogen into an animal, and then monitoring the humoral immune response to IgE CH4 decapeptide (SEQ ID N0:1) or an immunogenic analog thereof, as detailed in the Examples. Suitable animals include mice, rats, rabbits, guinea pigs, pigs, goats, sheep, or the like.
Another aspect of this invention provides a vaccine composition comprising an effective amount of one or more of the peptide immunogens of this invention in a pharmaceutically acceptable delivery system. Such vaccine compositions are used for prevention of atopic allergic reactions including allergic rhinitis, those of food allergies, asthma, anaphylaxis, and other IgE-mediated hypersens'itive reactions such as virally-induced asthma.
Accordingly, the subject peptide immunogens can be formulated as a vaccine composition using adjuvants, pharmaceutically-acceptable carriers or other ingredients routinely provided in vaccine compositions. Such formulations are readily determined by one of ordinary skill in the art and include formulations for immediate release and/or for sustained release, and for induction of systemic immunity and/or induction of localized mucosal immunity, which may be accomplished by, for example, immunogen entrapment by microparticles. The formulation may also include adjuvants or emulsifiers such as alum, incomplete Freund's adjuvant, liposyn, saponin, squalene, L121, emulsigen and ISA 720 and the like.
The vaccine of the present invention may be
administered by any convenient route including subcutaneous, oral, intramuscular, or other parenteral or enteral route. It may be administered as a single dose or in multiple doses. Immunization schedules are readily determined by the ordinarily skilled artisan.
The vaccine compositions of the instant invention contain an effective amount of one or more of the synthetic peptide immunogens containing the IgE CH4 decapeptide or its immunogenic analog and a pharmaceutically acceptable carrier. The dosage unit form may be formulated to contain about 0.5 μg to about 1 mg of each peptide per kg body weight . When delivered in multiple doses, the effective dose may be conveniently divided to contain the appropriate amounts per unit dosage form.
The vaccine compositions of the present invention may be formulated to contain a cocktail of two or more of the subject peptide immunogens to enhance immunoefficacy in a broader population and thus provide a better immune response against IgE CH4 decapeptide. For example, a cocktail of Peptide Nos. 19, 20, 21, 23, and 4 is useful. The composition may also be formulated to comprise lipopeptides to provide a built-in adjuvant. The immune response to synthetic IgE CH4 decapeptide- containing immunogens may also be improved by delivery through entrapment in or on biodegradable microparticles of the type described by O'Hagan et al i25) . The immunogens can be encapsulated with or without adjuvant, including covalently attached Pam3Cys, and such microparticles may carry an immune stimulatory adjuvant such as Freund's Incomplete Adjuvant or alum. The microparticles function to potentiate immune responses to the immunogen, including localized mucosal immunity. Such localized immunity is especially desirable, for example, for mucosally localized allergic reactions. Vaccine compositions in
microparticular form may also be formulated to provide time-controlled release for sustained or periodic responses, for oral administration, and for topical administration'25"26' . Examples of specific peptide immunogens are provided herebelow to illustrate the present invention and are to be used to limit the scope of the invention.
EXAMPLE 1 SYNTHESIS OF OCTAMERIC PEPTIDE IMMUNOGENS The following multimeric peptides were synthesized: Peptide No. 1
[LysThrLysGlySerGlyPhePheValPheGlyProGlyLysThrLysGlySerGly PhePheValPheGlyLysMet]8Lys4Lys2Lys, (SEQ ID NO:23)
Peptide No. 2
[LysThrLysGlySerGlyPhePheValPheGlyProGlyLysThrLysGlySerGly PhePheValPheGlyProGlyLysThrLysGlySerGlyPhePheValPheGlyLys Met]8Lys4Lys2Lys, (SEQ ID NO:13)
The synthesis of the multimeric peptides proceeds by the limited sequential propagation of a trifunctional amino acid to serve as a low molecular weight matrix core is the basis for the formation of a branching multimeric peptide antigen system. The trifunctional amino acid, Boc-Lys (Boc) , or di- (Boc) -Lys is most suitable since both N"- and Ne- amino acid groups are available as reactive ends. Thus, sequential propagation of di- (Boc) -Lys will generate 2n reactive ends.
For example,, the first coupling of di- (Boc) -Lys onto a solid phase resin will produce two reactive amino ends to bind two peptide chains. Sequential generations of a second, third, and fourth step with di- (Bpc) -Lys will therefore generate respectively tetravalent, octavalent, and hexadecavalent ends for binding multimeric peptide chains antigens. Such multimeric peptides are useful as
immunogens. Branched octameric Peptide Nos. 1 and 2 as described above were synthesized for use as immunogens. The branched antigens contain a small heptalysyl core surrounded by a layer of high density of uniform peptide- antigens around the core matrix. This design differs from the conventional peptide-carrier conjugate antigen which contains a large protein carrier such as PPD or KLH and a small peptide antigen randomly distributed on the surface of the protein carrier in many undefined forms.
The synthesis of the octameric peptide immunogens employs a combination of Boc-amino acid resin- bound benzhydrylamide and tBoc-chemistry. For example, an 8-branched heptalysyl core resin was prepared by coupling di-t-Boc Lys onto an extra low loading of 0.14 mmole/g MBHA (4-methylbenzhydrylamine) resin on a Biosearch 9500 instrument. Two coupling cycles of di- (Boc) -Lys for each was followed by two capping reacticns using 0.3 M acetylimidazole in DMF dimethylformamide.
Another two di- (Boc) -Lys couplings were added onto the first di- (NH2) Lys-resin. The substitution level of synthetic octameric resin was then determined by the ninhydrin test and found to have an appropriate level of free -NH2 groups, based on the theoretical coupling yield, and was used thereafter for the synthesis of octameric peptide immunogen according to the standard t-Boc procedure.
Acid-labile tert-butyloxycarbonyl (t-Boc) was used for the protection of N-oc amino acid. The following functional side-chain.protecting groups were used: O- benzyl for Thr, Ser, Glu and Tyr; Nδ-tosyl for Arg; BOM, i.e., BOC-Nim-Benzyloxymethyl for His, Ne- dichlorobenzyloxycarbonyl for Lys; S-4-methylbenzyl- for Cys; O-cyclohexyl for Asp and CHO for Trp.
The successive amino acids of Peptides No. 1 and No. 2 were added from the C- to N- terminus as dictated by
the sequences of Peptide Nos. 1 and 2 (SEQ ID NOS:23,13) .
The resultant octameric peptidyl resins for Peptide No. 1 and Peptide No. 2 were cleaved by anhydrous HF at Ooc for
1 hr in the presence of 10% v/v anisole. The released multimeric antigens were extracted with acetic acid, washed twice with ether and lyophilized to dryness. The lyophilized multimeric peptides were used as immunogens.
EXAMPLE 2
ACTIVE IMMUNIZATION WITH BRANCHED OCTAMERIC
PEPTIDE IMMUNOGENS USING CFA AND IFA AS ADJUVANTS
(a) Immunization procedure
Groups of Guinea Pigs (N=3 per group) were immunized with each of the two IgE CH4-related multimeric peptide immunogens (Peptide Nos. 1 and 2) and with Peptide No. 3 (SEQ ID NO:l) conjugated to KLH, according to the following protocol: Each animal was injected subcutaneously with a mixture (200 μL) of the peptide- based immunogen or conjugate (100 μg/mL) emulsified with an equal volume of complete Freund's adjuvant (CFA) . Subcutaneous injections of the peptide-based immunogen mixed with incomplete Freund's adjuvant (IFA) were repeated at days 21, 42, and 63.
(b) Assay of Guinea Pigs immune sera by measuring their Anti-IσE CH4 related peptide response
Anti-peptide antibody activity is determined by ELISA (enzyme-linked immunosorbentassay) using 96-well flat bottom microtiter plates which were coated with the corresponding immunogen. Aliquots (100 μL) of a peptide immunogen solution at a concentration of 5 μg/mL were incubated for 1 hour at 37°C. The plates were blocked by another incubation at 37°C for 1 hour with a 3% gelatin/PBS solution. The blocked plates were then dried and used for the assay. Aliquots (100 μL) of the test guinea pig sera, starting with a 1:10 dilution in a sample dilution buffer and ten-fold serial dilutions thereafter,
were added to the peptide coated plates. The plates were incubated for 1 hour at 37°C. Normal guinea pig serum was used as a control.
The plates were washed six times with 0.05% PBS/Tween® buffer. 100 μL of horseradish peroxidase labelled goat-anti-guinea pig antibody was added at a dilution of 1:1,000 in conjugate dilution buffer (Phosphate buffer containing 0.5M NaCl, and normal goat serum) . The plates were incubated for 1 hour at 37°C before being washed as above. Aliquots (100 μL) of o- phenylenediamine substrate solution were then added. The color was allowed to develop for 5-15 minutes before the enzymatic color reaction was stopped by the addition of 50 μL 2N H2S04. The A492nra of the contents of each well was read in a plate reader.
The immunogens, Peptide No. 1 and its closely related derivative Peptide No. 2, both in branching multimeric form, were found to be effective in eliciting antibodies specific to the IgE CH4 target sequence (SEQ ID NO:l) through an ELISA inhibition assay. The results, when compared to a control immunogen, the KLH conjugate of monomeric Peptide No. 3 (IgE CH4 decapeptide SEQ ID NO:l) showed that these two multimeric peptide antigens generated a higher level of antibody titers than the KLH conjugate.
The successful results of these immunization experiments indicated the generation of a Th epitope in the multimeric system as a result of insertion of Gly-Lys- Met at the C-terminus .of the peptide sequence (see SEQ ID NOS:23 and 13, Peptide Nos. 1 and 2) and indicated the importance of certain orientations for effective presentation to the immune system. Other experiments showed that merely making 8- or even 16-branched IgE peptide immunogens containing the IgE CH4 decapeptide (SEQ ID NO:l) or multiple repeats thereof, in other
orientations, were not effective in the induction of anti- IgE CH4 responses. In fact, out of a total of 19 branched multimeric constructs, Peptide Nos. 1 and 2 were the only ones to display enhanced immunogenicity. In this respect, the high immunogenicity observed with multimeric Peptide Nos. 1 and 2 required experimentation and was not predictable by one skilled in the art.
In addition, the results obtained suggest that a spacer sequence, i.e., Gly-Pro-Gly, incorporated between the short IgE CH4 segments, is necessary to allow free presentation of the epitopes conferred by the subunit sequence. The insertion of a spacer, i.e., Gly-Lys-Met, at the C-terminus prior to linkage to the branched lysine core resin was also found to be necessary for the immunogenicity of multimeric branched IgE CH4 decapeptide (SEQ ID N0:1) synthetic constructs.
EXAMPLE 3
IMMUNIZATION OF RATS WITH LINEAR IMMUNOGENS (SEQ ID NOS:15-22)
A. Immunoσen preparation: Peptide immunogens A-H (Table 3) are synthesized by solid phase synthesis using F-moc chemistry on an Applied Biosystems Peptide Synthesizer Model 430A or 431 according to manufacturer's instructions. After complete assembly of the peptide, the resin is treated according to standard procedures to cleave the peptide from the resin and deprotect the functional groups on amino acid side chains. The structure of the peptide immunogens from the amino terminus to the carbojςyl terminus is as follows: Peptide immunogen A is a linear peptide with three domains: 3 lysine residues (3K) , the hepatitis B surface antigen helper T cell epitope (HBsTh epitope) and IgE CH4 peptide. Peptide immunogen A is thus represented as 3K-HBsTh-IgE CH4 peptide. The actual sequences for Peptide immunogen A and for Peptide immunogens B-H are shown in Table 5 (SEQ
ID NOS:15-22) .
For immunizations at weeks 0, 2 and 5, each peptide immunogen is dissolved and combined with an adjuvant solution (Complete Freund's Adjuvant, Incomplete Freund's Adjuvant, or 0.2% Alum) to result in a final concentration of 0.5 mg/ml. The solution is stored at 4°C until use and vortexed for 3 to 5 min prior to injection. Each rat receives 100 μg per injection.
B. Immunization schedule and serum collection: Sprague-Dawley rats (n=5) are immunized subcutaneously
(s.c.) . Booster injections are given s.c. at weeks 2 and 5. Blood is collected at weeks 3, 6, 7 and 11.
Blood collection from the middle caudal artery is performed following anesthesia of the rats by intraperitoneal injection of 1 L of sodium pentobarbital
(64.8 mg/mL; Anthony Products Co., Accadia, CA) diluted 1 to 10 in 0.9% NaCl. The tails are kept in 48°C ± 0.5°C water for 2 min and rapidly massaged with paper towels
(i.e., milked) . Blood is collected immediately into a 5 mL syringe outfitted with a 23 gauge needle. Typically, 2 to 2.5 mL of blood is obtained. The serum is collected by centrifugation for 25 min at 3000 rpm. The serum is aliquoted in 300 μL volumes and stored frozen until used for ELISA assays.
TABLE 3 Sequences of Peptide Immunogens A-H
Peptide Immunogen Amino Acid Sequence
A 3K-HBsTh-IgECH4 Lys-Lys-Lys-Phe-Phe-Leu-Leu-Thr-Arg-
Ile-Leu-Thr-Ile-Pro-Gln-Ser-Leu-Asp- Lys-Thr-Lys-Gly-Ser-Gly-Phe-Phe-Val- Phe (SEQ ID NO:15)
B PT1Th-IgECH4 Lys-Lys-Leu-Arg-Arg-Leu-Leu-Tyr-Met-
Ile-Tyr-Met-Ser-Gly-Leu-Ala-Val-Arg- Val-His-Val-Ser-Lys-Glu-Glu-Gln-Tyr- Tyr-Asp-Tyr-Lys-Thr-Lys-Gly-Ser-Gly- Phe-Phe-Val-Phe (SEQ ID NO : 16 )
C PT1ATh- IgECH4 Tyr-Met-Ser-Gly-Leu-Ala-Val-Arg-Val-
His-Val-Ser-Lys-Glu-Glu-Lys-Thr-Lys- Gly-Ser-Gly-Phe-Phe-Val-Phe
(SEQ ID NO : 17 )
D TT1Th-IgECH4 Lys-Lys-Gln-Tyr- Ile-Lys-Ala-Asn-Ser-
Lys-Phe- Ile-Gly- Ile-Thr-Glu-Leu-Lys- Thr-Lys-Gly-Ser-Gly-Phe-Phe-Val-Phe
(SEQ ID NO : 18 )
E TT2Th- IgECH4 Lys-Lys-Phe-Asn-Asn-Phe-Thr-Val-Ser-
Phe-Trp-Leu-Arg-Val-Pro-Lys-Val-Ser- Ala-Ser-His-Leu-Lys-Thr-Lys-Gly-Ser- Gly-Phe-Phe-Val-Phe (SEQ ID NO : 19 )
F TT3Th- IgECH4 Tyr-Asp- Pro-Asn-Tyr-Leu-Arg-Thr-Asp-
Ser-Asp-Lys-Asp-Arg-Phe-Leu-Gln-Thr- Met -Val -Lys-Leu-Phe -Asn-Arg- Ile -Lys - Lys -Thr-Lys -Gly-Ser-Gly- Phe-Phe-Val- Phe ( SEQ ID NO : 20 )
G PT2Th- IgECH4 Gly-Ala-Tyr-Ala-Arg-Cys -Pro-Asn-Gly-
Thr-Arg-Ala-Leu-Thr-Val -Ala-Glu-Leu- Arg-Gly-Asn-Ala-Glu-Leu-Lys -Thr-Lys- Gly-Ser-Gly-Phe- Phe -Val -Phe
(SEQ ID NO : 21 )
H MVF1Th-IgECH4 Ser-Glu-Ile-Lys-Gly-Val-Ile-Val-His-
Arg-Leu-Glu-Gly-Val-Leu-Lys-Thr-Lys- Gly-Ser-Gly-Phe-Phe-Val-Phe
(SEQ ID NO:22)
EXAMPLE 4
IMMUNIZATION OF RATS WITH LINEAR IMMUNOGENS (SEQ ID NOS:37-50)
Linear peptide immunogens represented as A-Th- GG-IgE CH4, where A may be either NH2-, Lys-Lys (2K) , Lys- Lys-Lys (3K) , or an invasin domain (Inv) (SEQ ID NO:25), Th is a T helper peptide, GG is a Gly-Gly spacer, and IgE CH4 is the target decapeptide (SEQ ID NO:l) , are synthesized as described in Example 3. These peptide immunogens are shown in Table 4 as Peptide Immunogens Nos. 4-17 (SEQ ID NOS:37-50) . The synthesized and cleaved peptides are used to immunize rats to test for efficacy.
Efficacy is evaluated on groups of five rats by the experimental immunization protocol outlined below.
Experimental Design:
Immunogen: Peptide Nos. 4-17 (1 per trial) Dose: 100 μg per immunization Route: intramuscular
Adjuvant : Freund's Complete/Incomplete Dose Schedule: week 0 (FCA) , 3 and 6 weeks (IFA)
Bleed Schedule: weeks 0, 3, 6, 8, 10
Species: Sprague-Dawley rats
Group size: 5
Assay: ELISA for anti-peptide activity, solid-phase immunosorbent is monomeric Peptide No. 3 of the IgE CH4 decapeptide sequence (SEQ ID NO:1) . Blood is collected, processed into serum, and stored prior to titering by ELISA as described in Example 2, with the exception of using horseradish peroxidase- labelled goat anti-rat IgG antibody instead of goat anti- guinea pig IgG as the tracer.
TABLE 4 Sequences of Peptide Immunogens Nos. 4-17
Peptide Immunogen Amino Acid Sequence
4 TTiTh-GG- IgECHβ Lys-Lys-Gln-Tyr- Ile-Lys-Ala-Asn- Ser-Lys-Phe- Ile-Gly- Ile-Thr-Glu- Leu-Gly-Gly-Lys-Thr-Lys-Gly-Ser- Gly- Phe - Phe - Val - Phe
(SEQ ID NO . 37)
TT2Th-GG- IgECH4 Lys-Lys-Phe-Asn-Asn-Phe-Thr-Val- Ser-Phe-Trp-Leu-Arg-Val-Pro-Lys- Val-Ser-Ala-Ser-His-Leu-Gly-Gly- Lys-Thr-Lys-Gly-Ser-Gly-Phe-Phe- Val-Phe (SEQ ID NO : 38 )
6 PT1ATh-GG-IgECH4 Tyr-Met-Ser-Gly-Leu-Ala-Val-Arg- Val-His-Val-Ser-Lys-Glu-Glu-Gly- Gly-Lys-Thr-Lys-Gly-Ser-Gly-Phe- Phe-Val-Phe
(SEQ ID NO : 39 )
MVF2Th-GG-IgECH4 Gly- Ile-Leu-Glu-Ser-Arg-Gly- Ile- Lys-Ala-Arg- Ile-Thr-His-Val-Asp- Thr-Glu-Ser-Tyr-Gly-Gly-Lys-Thr- Lys-Gly-Ser-Gly-Phe-Phe-Val-Phe
(SEQ ID NO : 40)
TT4Th-GG- IgECH4 Trp-Val-Arg-Asp- Ile- Ile-Asp-Asp- Phe-Thr-Asn-Glu-Ser-Ser-Gln-Lys- Thr-Gly-Gly-Lys-Thr-Lys-Gly-Ser- Gly- Phe -Phe -Val -Phe
(SEQ ID NO : 41) TT5Th-GG- IgECH4 Asp-Val-Ser-Thr-Ile-Val-Pro-Tyr- Ile-Gly-Pro-Ala-Leu-Asn-His-Val- Gly-Gly-Lys-Thr-Lys-Gly-Ser-Gly- Phe-Phe-Val-Phe (SEQ ID NO:42) CTTh-GG- IgECH4 Ala-Leu-Asn-lie-Trp-Asp-Arg-Phe- Asp-Val-Phe-Cys-Thr-Leu-Gly-Ala- Thr-Thr-Gly-Tyr-Leu-Lys-Gly-Asn- Ser-Gly-Gly-Lys-Thr-Lys-Gly-Ser- Gly-Phe-Phe-Val-Phe
(SEQ ID NO:43) DTiTh-GG- IgECI^ Asp-Ser-Glu-Thr-Ala-Asp-Asn-Leu- Glu-Lys-Thr-Val-Ala-Ala-Leu-Ser- Ile-Leu-Pro-Gly-Ile-Gly-Cys-Gly- Gly-Lys-Thr-Lys-Gly-Ser-Gly-Phe- Phe-Val-Phe (SEQ ID NO:44) DT2Th-Gg- IgECH4 Glu-Glu-Ile-Val-Ala-Gln-Ser-Ile- Ala-Leu-Ser-Ser-Leu-Met-Val-Ala- Gln-Ala-Ile-Pro-Leu-Val-Gly-Glu- Leu-Val-Asp-Ile-Gly-Phe-Ala-Ala- Thr-Asn-Phe-Val-Glu-Ser-Cys-Gly- Gly-Lys-Thr-Lys-Gly-Ser-Gly-Phe- Phe-Val- (SEQ ID NO:45) PFTh-GG- IgECH4 Asp-Ile-Glu-Lys-Lys-Ile-Ala-Lys- Met-Glu-Lys-Ala-Ser-Ser-Val-Phe- Asn-Val-Val-Asn-Ser-Gly-Gly-Lys- Thr-Lys-Gly-Ser-Gly-Phe-Phe-Val- Phe (SEQ ID NO:46) SMTh-GG-IgECH4 Lys-Trp-Phe-Lys-Thr-Asn-Ala-Pro- Asn-Gly-Val-Asp-Glu-Lys-Ile-Arg- Ile-Gly-Gly-Lys-Thr-Lys-Gly-Ser- Gly-Phe-Phe-Val-Phe
(SEQ ID NO:47)
S95
39
TraTjTh-GG-IgECH* Gly-Leu-Gln-Gly-Lys-Ile-Ala-Asp-
Ala-Val-Lys-Ala-Lys-Gly-Gly-Gly- Lys-Thr-Lys-Gly-Ser-Gly-Phe-Phe- Val-Phe
(SEQ ID NO:48) TraT2Th-GG-IgECH4 Gly-Leu-Ala-Ala-Gly-Leu-Val-Gly-
Met-Ala-Ala-Asp-Ala-Met-Val-Glu- Asp-Val-Asn-Gly-Gly-Lys-Thr-Lys- Gly-Ser-Gly-Phe-Phe-Val-Phe
(SEQ ID NO:49) TraT3Th-GG-IgECH4 Ser-Thr-Glu-Thr-Gly-Asn-Gln-His-
His-Tyr-Gln-Thr-Arg-Val-Val-Ser- Asn-Ala-Asn-Lys-Gly-Gly-Lys-Thr-
Lys-Gly-Ser-Gly-Phe-Phe-Val-Phe
(SEQ ID NO: 50)
EXAMPLE 5
IMMUNIZATION OF RATS WITH LINEAR
IMMUNOGENS (SEQ ID NOS:51-56.62)
AND LINEAR IMMUNOGENS OF REVERSE POLARITY (SEQ ID NOS:57-60)
Peptide immunogens Nos. 18-23 (ID SEQ ID NOS:51-56) as shown in Table 5, were synthesized as described in Example 3. The formula for peptide immunogens Nos. 18-23 may be represented as A-Th-GG-IgECH4, wherein A is either the N terminus, Lys-Lys (2K) , Lys-Lys-Lys (3K) , or the invasin domain (Inv) (SEQ ID NO:25) separated from the Th sequence by a spacer GG; Th is selected from the group consisting of HBS Th, PTX Th, PT2 Th, MVF1 Th, or TT3 Th; GG is a Gly-Gly spacer; and IgECH4 is the IgE CH4 decapeptide (SEQ ID NO:l) .
Peptide immunogens with SEQ ID NOS:57-60, also shown in Table 5, as Peptide Nos. 24-27, were synthesized in an identical fashion to the Peptide Nos. 18-23. These peptides may be represented as IgECH4-GG-Th. These peptides are equivalent to Peptide Nos. 19,20,21,23 (Table 5) in terms of IgECH4 decapeptide, spacer, and Th sequences except that the decapeptide/Th polarity was reversed, i.e.,. the IgE CH4 decapeptide (SEQ ID NO:l) was on the N terminus while Th was located on the C terminus. These peptide immunogens were used to immunize rats as described in the experimental protocol below, for comparison and demonstration of efficacy. Experimental Design:
Immunogen: Peptide Nos. 18-28 (1 per group) (SEQ ID NOS:51-60 and 62)
Dose: 100 μg per immunization Route: intramuscular Adjuvant: Freund's Complete/Incomplete for Peptide Nos. 18-27, 0.4% Alum for
Peptide No. 28 Dose Schedule: week 0 (FCA) , 3 and 6 weeks (IFA) for
Peptide Nos. 8-27, Alum for Peptide No. 28 on weeks 0, 3, and 6 Bleed Schedule: weeks 0, 3, 6, 8, 10 Species: Sprague-Dawley rats Group size: 5 for Peptide Nos. 27-28, 4 for Peptide No. 28 Assay: ELISA for anti-peptide activity, solid-phase substrate is Peptide No. 3 (SEQ ID N0:1) . Blood was collected, processed into serum, and stored prior to titering by ELISA as described in Example 2 with the exception of substituting horseradish peroxidase- labelled goat anti-rat IgG antibody for anti-guinea pig IgG as the tracer. All sera were assayed by anti-peptide ELISA and those samples which gave A492nm values of ≥ 0.2 at a 1:100 dilution were recorded as seropositive.
The immunopotencies of Peptide immunogens Nos. 18-28 (SEQ ID NOS:51-60, and 62) were evaluated by the anti-peptide ELISA and are shown in Table 6 as the number of rats in each group of 4 or 5 that converted to seropositive reactivity for IgE CH4 Peptide No. 3 on weeks 6 and 8 (i.e., A492ram ≥ 0.2 at a 1:100 dilution) , in response to the experimental immunizations.
The peptide immunogens of this Example of polarity Th-GG-IgECH4 (Peptide Nos. 18-23 and 28, SEQ ID NOS:51-56 and 62) showed significant efficacy for the induction of antibodies to the IgE CH4 decapeptide (Peptide No. 3, SEQ ID NO:l) . All 6 groups of rats immunized with the peptide immunogens of this polarity (Peptide Nos. 18-23, 28) showed significant conversion to seropositivity compared to the control. Prevalences of
seroconversion for the groups varied from 1/5 to 5/5 by week 6 and seroconversion prevalences continued to increase between weeks 6 and 8 in response to the third dose of immunogens. Peptide immunogen No. 18 containing the HBS Th peptide sequence, Peptide immunogen No. 19 with the MVF1 Th peptide and Peptide No. 28 containing the PTiTh peptide sequence were the most effective, with seroconversion prevalences of 4/5, 5/5 and 4/4, respectively, by week 8. Comparison of the
10 immunogenicities of Peptide immunogens Nos. 21 and 22 (SEQ ID NOS:54, 55) demonstrates that the Inv domain peptide provided significant improvement by week 8 to the immune stimulatory capability of the PT2 Th-containing peptide (Table 6) .
15 In contrast, the analogous peptide immunogens with reversed Th polarity (Peptide immunogens Nos. 24-27, SEQ ID NOS:57-60) failed to display significant immunopotency for the seroconversion of rats. This poor immunopotency shows that a Th-GG-IgECH4 amino to carboxyl
20 terminus polarity is critical to the immunogenicity of the linear peptide immunogens of the invention. A determination of efficacy for one orientation of target peptide and Th over the other was not predictable by one skilled in the art and is unexpected.
TABLE 5
25 Sequences of Peptide Immunogens Nos. 18-28
Peptide Immunogen Amino Acid Sequence
30 18 3K-HBsTh-GG-IgECH4 Phe-Phe-Leu-Leu-Thr-Arg-Ile-Leu-
Thr-Ile-Pro-Gln-Ser-Leu-Asp-Gly- Gly-Lys-Thr-Lys-Gly-Ser-Gly-Phe- Phe-Val-Phe (SEQ ID NO:51)
!%: 20 1
MVF1Th-GG- IgECH4 Leu-Ser-Glu- Ile-Lys-Gly-Val- Ile- Val-His-Arg-Leu-Glu-Gly-Val-Gly- Gly-Lys-Thr-Lys-Gly-Ser-Gly-Phe- Phe-Val-Phe (SEQ ID NO : 52 ) PTiTh-GG- IgECHi Lys-Lys-Leu-Arg-Arg-Leu-Leu-Tyr- Met- Ile-Tyr-Met-Ser-Gly-Leu-Ala- Val-Arg-Val-His-Val-Ser-Lys-Glu- Glu-Gln-Tyr-Tyr-Asp-Tyr-Gly-Gly- Lys-Thr-Lys-Gly-Ser-Gly-Phe-Phe- Val-Phe (SEQ ID NO : 53 ) PT2Th-GG- IgECH4 Gly-Ala-Tyr-Ala-Arg-Cys-Pro-Asn- Gly-Thr-Arg-Ala-Leu-Thr-Val-Ala- Glu-Leu-Arg-Gly-Asn-Ala-Glu-Leu- Gly-Gly-Lys-Thr-Lys-Gly-Ser-Gly- Phe- Phe -Val -Phe (SEQ ID NO : 54 ) Inv-GG-PT2Th-GG- IgECH4 Thr-Ala-Lys-Ser-Lys-Lys-Phe-Pro- Ser-Tyr-Thr-Ala-Thr-Tyr-Gln-Phe- Gly-Gly-Gly-Ala-Tyr-Ala-Arg-Cys- Pro-Asn-Gly-Thr-Arg-Ala-Leu-Thr- Val-Ala-Glu-Leu-Arg-Gly-Asn-Ala- Glu-Leu-Gly-Gly-Lys-Thr-Lys-Gly- Ser-Gly-Phe-Phe-Val-Phe
(SEQ ID NO : 55 ) TT3Th-GG- IgECH4 Tyr-Asp-Pro-Asn-Tyr-Leu-Arg-Thr- Asp-Ser-Asp-Lys-Asp-Arg-Phe-Leu- Gln-Thr-Met -Val-Lys-Leu-Phe-Asn- Asp-Arg-Phe-Leu-Gln-Thr-Met-Val- Lys-Leu-Phe-Asn-Arg- Ile-Lys-Gly- Gly-Lys-Thr-Lys-Gly-Ser-Gly-Phe- Phe-Val-Phe (SEQ ID NO : 56 ) IgECH4-GG-MVF1Th Lys-Thr-Lys-Gly-Ser-Gly-Phe-Phe- Val-Phe-Gly-Gly-Leu-Ser-Glu- Ile- Lys-Gly-Val- Ile-Val-His-Arg-Leu- Glu-Gly-Val (SEQ ID NO : 57) IgECH -GG-PTiTh Lys-Thr-Lys-Gly-Ser-Gly-Phe-Phe- Val-Phe-Gly-Gly-Lys-Lys-Leu-Arg- Arg-Leu-Leu-Tyr-Met- Ile-Tyr-Met- Ser-Gly-Leu-Ala-Val-Arg-Val-His- Val-His-Lys-Glu-Glu-Gln-Tyr-Tyr- Asp-Tyr (SEQ ID NO : 58 )
IgECH4-GG-PT2Th Lys-Thr-Lys-Gly-Ser-Gly-Phe-Phe- Val-Phe-Gly-Gly-Gly-Ala-Tyr-Ala- Arg-Cys-Pro-Asn-Glu-Thr-Arg-Ala- Leu-Thr-Val-Ala-Glu-Leu-Arg-Gly- Asn-Ala-Glu-Leu (SEQ ID NO: 59) IgECH4-GG-TT3Th Lys-Thr-Lys-Gly-Ser-Gly-Phe-Phe- Val-Phe-Gly-Gly-Tyr-Asp-Pro-Asn- Tyr-Leu-Arg-Thr-Asp-Ser-Asp-Lys- Asp-Arg-Phe-Leu-Gln-Thr-Met-Val- Lys-Leu-Phe-Asn-Asp-Arg-Phe-Leu- Gln-Thr-Met-Val-Lys-Leu-Phe-Asn- Arg-Ile-Lys (SEQ ID NO:60)
Lys-Lys-Leu-Arg-Arg-Leu-Leu-Tyr- Met-Ile-Tyr-Met-Ser-Gly-Leu-Ala- Val-Arg-Val-His-Val-Ser-Lys-Glu- Glu-Gln-Tyr-Tyr-Asp-Tyr-Lys-Thr- Lys-Gly-Ser-Gly-Phe-Phe-Val-Phe
(SEQ ID NO: 62)
TABLE 6
Animals Seroconverted/group*
Peptide Immunogen
Week 6 Week 8
18 3K-HBsTh-GG-IgECH4 (SEQ ID NO: 51)
19 MVF1Th-GG-IgECH4 (SEQ ID NO: 52)
(SEQ ID NO: 53)
21 PT2Th-GG-IgECH4
(SEQ ID NO: 54)
22 Inv-GG-PT2-GG-IgECH4
(SEQ ID NO: 55)
23 TT3Th-GG-IgECH4
(SEQ ID NO: 56)
24 IgECH4-GG-MVF1Th
(SEQ ID NO: 57)
25 IgECH.j-GG-PTiTh
(SEQ ID NO: 58)
26 IgECH4-GG-PT2Th
(SEQ ID NO: 59)
27 IgECH4-GG-TT3Th
(SEQ ID NO: 60)
28 PTiTh-IgECH*
(SEQ ID NO: 62)
Control Immunization - (No peptide)
*5 animals per group for Peptide Nos. 18-27, 4 animals for Peptide No. 28
EXAMPLE 6
COCKTAIL OF LINEAR IMMUNOGENS FURTHER BROADENS THE RESPONSIVE POPULATION
Establishing the relative efficacies of the many different linear constructs containing IgE CH4 decapeptide and Th (Examples 3-5) permits selection of useful peptide immunogens to formulate a cocktail vaccine composition. Individual Th-GG-IgECH4 constructs carrying immunodominant promiscuous Th peptides derived from measles virus F protein, tetanus toxin and pertussis toxin (Peptide Nos. 19-23) were proven by the study of Example 5 to be efficacious in eliciting antibody responses to the IgECH4 decapeptide (SEQ ID N0:1) . A formulation containing a mixture of these linear peptides may provide a desired maximum immunogenicity in a genetically diverse population.
The immunopotency of such a composition formulated to contain a mixture of synthetic peptides with the preferred "A-Th-GG-IgECH4" polarity, Peptide immunogens Nos. 19, 20, 21, 23 (Table 5) and Peptide immunogen No. 4 (Table 4, Example 4) were evaluated in rats by the protocol described in Example 5. Each animal in a group of 5 rats were immunized with 100 μg doses of an equimolar formulation of the 5 peptides, i.e. 20 μg of each peptide. The number of rats that converted to seropositive reactivity by weeks 5 and 8 were 5 out of 5 (i.e., 100%) at both time intervals.
The results demonstrate that a vaccine comprising a cocktail'of the peptide immunogens of the present invention provides improved immunogenicity. It also indicates the potential for this mixture, and of like cocktails composed of individually efficacious peptides, to induce immunotherapeutic antibody responses in the genetically diverse human population.
EXAMPLE 7
IMMUNIZATIONS WITH COCKTAILS OF EFFICACIOUS LINEAR IMMUNOGENS
Establishing the relative efficacies of the many different linear constructs containing IgE CH4 decapeptide and Th (Examples 3-5) permits selection of useful peptides for a cocktail of immunogens. Individual constructs carrying a Gly-Gly spacer and promiscuous Th peptides derived from measles virus F protein, hepatitis B surface antigen, tetanus toxin and pertussis toxin in the immunogen cocktail are demonstrated to be efficacious (Table 6) . A mixture of these linear peptide immunogens with specific polarity with proven efficacy may thus provide maximum immunogenicity in a genetically diverse population. The protocol below has been designed to demonstrate efficacy for compositions of the invention formulated as mixtures of synthetic peptide immunogens containing preferred "A-Th-GG-IgECH4" constructs. Experimental Design:
Immunogens: (1) Cocktail 1: Peptide Nos. 18, 19, 20
(2) Cocktail 2: Peptide Nos. 18, 19, 22
(3) Positive Control- KLH conjugate of Peptide 3 (One immunogen per group of rats)
Dose: Molar equivalents of each synthetic peptide or IgE CH4 equivalent, to equal either 100 μg or 33.3 μg of peptide per immunization Route: .intramuscular Adjuvants: (1) Freund's Complete/Incomplete
(2) 0.4% Alum (Aluminum hydroxide) (One of either adjuvant per immunogen per group) Dose Schedule: week 0, 2 and 4 weeks
(CFA/IFA groups receive CFA week 0,
IFA weeks 2 and 4. Alum groups receive Alum formulations for all 3 doses)
Bleed Schedule: weeks 0, 3, 6 and 8
Species: Sprague-Dawley rats/group
Group size: 5, 6 groups
Assay: ELISA for anti-peptide activity, solid-phase immunosorbent is Peptide
NO. 3 (SEQ ID NO:l) .
Blood is collected, processed into serum, and stored prior to titering by ELISA as described in Example 5.
This experiment is designed to demonstrate improved performance of the immunogens of the present invention as compared to the known immunogens of the prior art114,15'. The results are useful for the evaluation of two mixtures of efficacious peptide immunogens, each containing three Th peptides, demonstrate the usefulness of the immune stimulatory Inv domain (cocktail 2 contains Inv, cocktail 1 does not) , and the efficacy of the adjuvant, Alum, in a vaccine composition of the invention.
EXAMPLE 8 CLINICAL TRIAL USING COCKTAILS OF IMMUNOGENS
Establishing the relative efficacies of the many different constructs containing IgE CH4 decapeptide and Th (Examples 3-5). permits selection of representative peptides for a cocktail of immunogens. Individual constructs carrying a Gly-Gly spacer and Th peptide sequences from measles virus F, hepatitis B surface antigen, tetanus toxin and pertussis toxin in the immunogen cocktail are of demonstrated efficacy (Table 6) and are promiscuous for multiple human HLA DR antigens, so
as to provide maximum immunogenicity in a genetically diverse human population. Moreover, because these Th peptides are derived from children's vaccines, childhood vaccinations are a potential source of Th memory in an immunized human population. Thus, children's vaccines have the potential to afford enhanced immunopotency to anti-allergy vaccines comprised of mixtures of such Th peptides. The clinical protocol below has been designed to demonstrate efficacy for compositions of the invention formulated as a mixture of such linear "A-Th-Spacer-IgE Ch4 decapeptide" peptide immunogens, in a widely acceptable adjuvant, Alum. Experimental Design:
Subjects: Hay fever patients Season & Duration: Hay fever seasons, 8 weeks
Groups: 4 groups, 1 group/immunogen/dose N=15 per group, 12 receive immunogen, 3 receive placebo Immunogen: Cocktail 1: Peptide Nos. 18, 19, 20, 23 Adjuvant: 0.2% Alum
Dose: Molar equivalents of each synthetic peptide to equal 500 μg or 125 μg of peptide per dose Route: intramuscular Dose Schedule: week 0, and 4 weeks Evaluation schedule: weeks 0, 4, and 6
Blood is collected, processed into serum, and stored prior to titering by ELISA as described in Example 5.
Efficacy and safety of the vaccine composition "cocktail 1" are evaluated serologically, by skin reaction tests, the rate of patient usage of hay fever medication, physical examination of patients for allergic symptoms and adverse reactions, and interviewing the patients to obtain their subjective assessments of the effect of using the
products. Serological evaluations include the aforementioned ELISA for antipeptide titer, and a standard automated spectrofluorimetric assay to determine reduction in histamine levels115' as well as to ascertain that the products do not trigger histamine release. The skin test is an intradermal test in which a standardized solution of allergens is injected into the upper layers of the skin. Reactions to the allergens are quantitated by determining the area of the typical "wheal and flare" produced in response to the allergens. The expected results include significant improvement in allergic symptoms at the endpoint of the study, and no evidence of histamine release triggered by the vaccine composition of the invention.
This experiment is designed to demonstrate the clinical efficacy of the invention. The results provide an evaluation of a mixture of "A-Th-Spacer-IgE CH4 decapeptide" immunogens containing four Th peptide sequences formulated with a pharmaceutically acceptable adjuvant, Alum.
EXAMPLE 9 IN VITRO ASSAY DEMONSTRATES EFFICACY OF IgE CH4 DECAPEPTIDE-SPECIFIC ANTIBODIES
Passively-sensitized human basophils are used in a well- known histamine-release assay for an in vitro evaluation of antibodies induced by immunizations with IgE CH4 decapeptide immunogens. Human basophils are prepared from the venous blood of volunteers and then passively sensitized with IgE specific for benzylpenicilloyl-human serum albumin conjugate (BPO-HSA) that is prepared from the blood of donors hyperimmunoglobulemic for BPO-HSA- specific IgE. Histamine release by the sensitized basophils is affected by the addition of either BPO-HSA or IgE CH4 Peptide No. 3 (SEQ ID NO:l) . Prior to the addition of the agents to induce histamine release, the basophils are combined with serial dilutions of antiserum to IgE CH4 decapeptide (SEQ ID NO:l) or pre-immune control serum. Samples are analyzed for histamine release by the automated fluorescence technique. The percentage of histamine release is calculated from the ratio of sample to total basophil histamine content after spontaneous release is subtracted from both127' . The capacity of the experimental antiserum to inhibit histamine release is demonstration of in vitro efficacy.
The ability of the IgE CH4 Peptide No. 3 (SEQ ID NO:l) to induce histamine release in a concentration-dependent manner was demonstrated by this assay. The results, presented in Table 7, showed that the IgE CH4 Peptide No. 3 (SEQ ID NO:l) induced histamine release by human basophils and served to validate the relevance of SEQ ID NO:l and corresponding antibodies for the human allergic response.
TABLE 7
Inducer % Net Histamine Release*
Peptide No. 3
150 μg/mL (1.3 X 10'4M) 30%
60 μg/mL (7 X 10"5M) 13
6 μg/mL (7 X 10"6M) 2 BPO-HSA
0.1 μg/mL 63%
Corrected by subtraction of spontaneous histamine release, 9%
° SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANTS: United Biomedical, Inc. & WANG, Chang Yi
5 (ii) TITLE OF INVENTION: SYNTHETIC PEPTIDE BASED IMMUNOGENS FOR THE TREATMENT OF ALLERGY
(iii) NUMBER OF SEQUENCES: 62
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Maria C.H. Lin
(B) STREET: 345 Park Avenue 0 (C) CITY: New York
(D) STATE: NY
(E) COUNTRY: USA
(F) ZIP: 10154
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk m (B) COMPUTER: IBM PC compatible D (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: WordPerfect 5.1
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE: 24-MAR-1995
(C) CLASSIFICATION: 0
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/328,912
(B) FILING DATE: 25-OCT-1994
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/218,461
(B) FILING DATE: 28-MAR-1994
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/060,798
(B) FILING DATE: 10-MAY-1993
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 07/847,745 0 (B) FILING DATE: 06-MAR-1992
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 07/637,364
(B) FILING DATE: 04-JAN-1991
5
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Maria C.H. Lin
(B) REGISTRATION NUMBER: 29,323
(C) REFERENCE/DOCKET NUMBER: 1151-4061US4
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 212-758-4800.
(B) TELEFAX: 212-751-6849
(2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10
(B) TYPE: amino acid (C) STRANDEDNESS : not applicable
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(x) PUBLICATION INFORMATION:
(A) AUTHORS: Stanworth et al .
(B) TITLE: The Role Of Non-Antigen Receptors In Mast Cell Signalling Processes
(C) JOURNAL: Molecular Immunology (D) -VOLUME: 21
(E) ISSUE: 12
(F) PAGES: 1183-1190
(G) DATE: 1984
(J) PUBLICATION DATE: (K) -RELEVANT RESIDUES: 497 to 506
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1 :
Lys Thr Lys Gly Ser Gly Phe Phe Val Phe 1 5 10
(3) INFORMATION FOR SEQ ID NO:2 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 325
(B) TYPE: amino acids
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY:' Unknown
(ii) MOLECULE TYPE: Poylpeptide e-chain of human IgE
(x) PUBLICATION INFORMATION:
(A) AUTHORS: Dorrington and Bennich
(B) TITLE:
(C) JOURNAL: Immunology Review
(D) VOLUME: 41
(E) ISSUE:
(F) PAGES: 3-25
(G) DATE: 1978
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:2 :
Val Cys Ser Arg Asp Phe Thr Pro Pro Thr Val Lys lie Leu Gin 5 10 15
Ser Ser Cys Asp Gly Gly Gly His Phe Pro Pro Thr lie Gin Leu
20 25 30
Leu Cys Leu Val Ser Gly Tyr Thr Pro Gly Thr lie Asn lie Thr
35 40 45
Trp Leu Glu Asp Gly Gin Val Met Asp Val Asp Leu Ser Thr Ala
50 55 60
Ser Thr Thr Gin Glu Gly Glu Leu Ala Ser Thr Gin Ser Gin Leu 65 70 75
Thr Leu Ser Gin Lys His Trp Leu Ser Asp Arg Thr Tyr Thr Cys
80 85 90
Gin Val Thr Tyr Gin Gly His Thr Phe Gin Asp Ser Thr Lys Lys
95 100 105
Cys Ala Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg
110 115 120
Pro Ser Pro Phe Asp Leu Phe lie Arg Lys Ser Pro Thr lie Thr
125 130 135
Cys Leu Val Leu Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu
140 145 150
Thr Trp Ser Arg Ala Ser Gly Lys Pro Val Asn Asn Ser Thr Arg
155 160 165
Lys Glu Glu Lys Gin Arg Asn Gly Thr Leu Thr Val Thr Ser Thr
170 175 180 Leu Pro Val Gly Thr Arg Asp Trp lie Glu Gly Glu Thr Tyr Gin
185 190 195
Cys Arg Val Thr His Pro His Leu Pro Arg Ala Leu Met Arg Ser
200 205 210
Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala
215 220 225
Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu
230 235 240
Ala Cys Leu lie Gin Asn Phe Met Pro Glu Asp lie Ser Val Gin
245 250 255
Trp Leu His Asn Glu Val Gin Leu Pro Asp Ala Arg His Ser Thr
260 265 270
Thr Gin Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Ser
275 280 285
Arg Leu Glu Val Thr Arg Ala Glu Trp Gin Glu Lys Asp Glu Phe 290 295 300 lie Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser Gin Thr Val
305 310 315
Gin Arg Ala Val Ser Val Asn Pro Gly Lys
320 325
(4) INFORMATION FOR SEQ ID NO:3 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 175
(B) TYPE: amino acids
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: Unknown
(ii) MOLECULE TYPE: Polypeptide .e-chain of rat IgE (x) PUBLICATION INFORMATION:
(A) AUTHORS: Kindsrogel et al.
(B) TITLE:
(C) JOURNAL: DNA
(D) VOLUME: 1
(E) ISSUE:
(F) PAGES: 335-343 (G) DATE: 1982
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:3:
Asn Leu Asn lie Thr Gin Gin Gin Trp Met Ser Glu Ser Thr Phe
5 10 15
Thr Cys Lys Val Thr Ser Gin Gly Glu Asn Tyr Trp Ala His Thr
20 25 30
Arg Arg Cys Ser Asp Asp Glu Pro Arg Gly Val lie Thr Tyr Leu
35 40 45 lie Pro Pro Ser Pro Leu Asp Leu Tyr Glu Asn Gly Thr Pro Lys
50 55 60
Leu Thr Cys Leu Val Leu Asp Leu Glu Ser Glu Glu Asn lie Thr
65 70 75
Val Thr Trp Val Arg Glu Arg Lys Lys Ser lie Gly Ser Ala Ser 80 85 90
Gin Arg Ser Thr Lys His His Asn Ala Thr Thr Ser lie Thr Ser
95 100 105 lie Leu Pro Val Asp Ala Lys Asp Trp lie Glu Gly Glu Gly Tyr
110 115 120
Gin Cys Arg Val Asp His Pro His Phe Pro Lys Pro lie Val Arg
125 130 135
Ser lie Thr Lys Ala Leu Gly Leu Arg Ser Ala Pro Glu Val Tyr 140 145 150
Val Phe Leu Pro Pro Glu Glu Glu Glu Lys Asn Lys Arg Thr Leu
155 160 165 Thr Cys Leu lie Gin Asn Phe Phe Pro Glu
170 175
(5) INFORMATION FOR SEQ ID NO:4 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 315
(B) TYPE: amino acids
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: Unknown
(ii) MOLECULE TYPE: Polypeptide e-chain of mouse IgE
(x) PUBLICATION INFORMATION:
(A) AUTHORS: Ishida et al .
(B) TITLE:
(C) JOURNAL: EMBO
(D) VOLUME: 1
(E) ISSUE:
(F) PAGES: 1117-1123 (G) DATE: 1982
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:4 :
Val Arg Pro Val Thr His Ser Leu Ser Pro Pro Trp Ser Tyr Ser
5 10 15 lie His Arg Cys Asp Pro Asn Ala Phe His Ser Thr lie Gin Leu
20 25 30 Tyr Cys Phe lie Tyr Gly His lie Leu Asn Asp Val Ser Val Ser
35 40 45
Trp Leu Met Asp Asp Arg Glu lie Thr Asp Thr Leu Ala Gin Thr
50 55 60
Val Leu lie Lys Glu Glu Gly Lys Leu Ala Ser Thr Cys Ser Lys
65 70 75
Leu Asn lie Thr Glu Gin Gin Trp Met Ser Glu Ser Thr Phe Thr
80 85 90
Cys Arg Val Thr Ser Gin Gly Cys Asp Tyr Leu Ala His Thr Arg
95 100 105
Arg Cys Pro Asp His Glu Pro Arg Gly Ala lie Thr Tyr Leu lie
110 115 120
Pro Pro Ser Pro Leu Asp Leu Tyr Gin Asn Gly Ala Pro Lys Leu
125 130 135
Thr Cys Leu Val Leu Asp Leu Glu Ser Glu Lys Asn Val Asn Val *. 140 145 150
Thr Trp Asn Gin Glu Lys Lys Thr Ser Val Ser Ala Ser Gin Trp
155 160 165
Tyr Thr Lys His His Asn Asn Ala Thr Thr Ser lie Thr Ser lie
170 175 180
Leu Pro Val Val Ala Lys Asp Trp lie Glu Gly Tyr Gly Tyr Gin
185 190 195
Cys lie Val Asp Arg Pro Asp Phe Pro Lys Pro lie Val Arg Ser
200 205 210 lie Thr Leu Pro Gin Val Ser Gin Arg Ser Ala Pro Glu Val Tyr
215 220 225
Val Phe Pro Pro Pro Glu Glu Glu Ser Glu Asp Lys Arg Thr Leu
230 235 240
Thr Cys Leu lie Gin Asn. Phe Phe Pro Glu Asp lie Ser Val Gin
245 250 255 Trp Leu Gly Asp Gly Lys Leu lie Ser Asn Ser Gin His Ser Thr
260 265 270
Thr Thr Pro Leu Lys Ser Asn Gly Ser Asn Gin Gly Phe Phe lie
275 280 285
Phe Ser Arg Leu Glu Val Ala Lys Thr Leu Trp Thr Gin Arg Lys
290 295 300
Gin Phe Thr Cys Gin Val lie His Glu Ala Leu Gin Lys Pro Arg
305 310 315
(6) INFORMATION FOR SEQ ID NO:5 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15
(B) TYPE: amino acid
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5 :
Phe Phe Leu Leu Thr Arg lie Leu Thr lie Pro Gin Ser Leu Asp 1 5 10 15
(7) INFORMATION FOR SEQ ID NO: 6 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28
(B) TYPE: amino acid
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6 :
Lys Lys Leu Arg Arg Leu Leu Tyr Met lie Tyr Met Ser Gly Leu 1 5 10 15
Ala Val Arg Val His Val Ser Lys Glu Glu Gin Tyr Tyr Asp Tyr
20 25 30
(8) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17
(B) TYPE: amino acid
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
Lys Lys Gin Tyr lie Lys Ala Asn Ser Lys Phe lie Gly lie Thr 1 5 10 15
Glu Leu
(9) INFORMATION FOR SEQ ID NO:8 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22
(B) TYPE: amino acid
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
Lys Lys Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro 1 5 10 15
Lys Val Ser Ala Ser His Leu
20
(10) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15
(B) TYPE: amino acid (C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
Tyr Met Ser Gly Leu Ala Val Arg Val His Val Ser Lys Glu Glu 1 5 10 15
(11) INFORMATION FOR SEQ ID NO: 10
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 (B) TYPE: amino acid
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
Tyr Asp Pro Asn Tyr Leu Arg Thr Asp Ser Asp Lys Asp Arg Phe 1 5 10 15
Leu Gin Thr Met Val Lys Leu Phe Asn Arg He Lys
20 25
(12) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24
(B) TYPE: amino acid
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
Gly Ala Tyr Ala Arg Cys Pro Asn Gly Thr Arg Ala Leu Thr Val 1 5 10 15
Ala Glu Leu Arg Gly Asn Ala Glu Leu
20
(13) INFORMATION FOR SEQ ID NO: 12:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 (B) TYPE: amino acid
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
Ser Glu He Lys Gly Val He Val His Arg Leu Glu Gly Val Leu 1 5 10 15
(14) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 (B) TYPE: amino acids
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE:
(A) DESCRIPTION: peptide
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:13:
Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Gly Pro Gly Lys Thr
5 10 15
Lys Gly Ser Gly Phe Phe Val Phe Gly Pro Gly Lys Thr Lys Gly
20 25 30
Ser Gly Phe Phe Val Phe Gly Lys Met
35
(15) INFORMATION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21
(B) TYPE: amino acids (C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE:
(A) DESCRIPTION: peptide
(xi) SEQUENCE DESCRIPTION:SEQ ID NO: 14 :
Val Ser Phe Gly Val Trp He Arg Thr Pro Pro Ala Tyr Arg Pro 1 5 10 15
Pro Asn Ala Pro He Leu
20
(16) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28
(B) TYPE: amino acid
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
Lys Lys Lys Phe Phe Leu Leu Thr Arg He Leu Thr He Pro Gin 1 5 10 15
Ser Leu Asp Lys Thr Lys .Gly Ser Gly Phe Phe Val Phe
20 25
(17) INFORMATION FOR SEQ ID NO:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38
(B) TYPE: amino acid
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Lys Lys Leu Arg Arg Leu Leu Tyr Met He Tyr Met Ser Gly Leu 1 5 10 15
Ala Val Arg Val His Val Ser Lys Glu Glu Gin Tyr Tyr Asp Tyr
20 25 30
Lys Thr Lys Gly Ser Gly Phe Phe Val Phe
35 40
(18) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25
(B) TYPE: amino acid
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17
Tyr Met Ser Gly Leu Ala Val Arg Val His Val Ser Lys Glu Glu 1 5 10 15
Lys Thr Lys Gly Ser Gly Phe Phe Val Phe , 20 25
(19) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27
(B) TYPE: amino acid
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:
Lys Lys Gin Tyr He Lys Ala Asn Ser Lys Phe He Gly He Thr 1 5 10 15
Glu Leu Lys Thr Lys Gly Ser Gly Phe Phe Val Phe
20 25
(20) INFORMATION FOR SEQ ID NO:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32
(B) TYPE: amino acid
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:
Lys Lys Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro 1 5 10 15
Lys Val Ser Ala Ser His Leu Lys Thr Lys Gly Ser Gly Phe Phe
20 25 30
Val Phe
(21) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37
(B) TYPE: amino acid
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
Tyr Asp Pro Asn Tyr Leu Arg Thr Asp Ser Asp Lys Asp Arg Phe
1 5 10 15 Leu Gin Thr Met Val Lys Leu Phe Asn Arg He Lys Lys Thr Lys
20 25 30
Gly Ser Gly Phe Phe Val Phe
35
(22) INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34
(B) TYPE: amino acid
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
Gly Ala Tyr Ala Arg Cys Pro Asn Gly Thr Arg Ala Leu Thr Val 1 5 10 15
Ala Glu Leu Arg Gly Asn Ala Glu Leu Lys Thr Lys Gly Ser Gly
20 25 30
Phe Phe Val Phe
(23) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25
(B) TYPE: amino acid
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
Ser Glu He Lys Gly Val He Val His Arg Leu Glu Gly Val Leu 1 5 10 15
Lys Thr Lys Gly Ser Gly Phe Phe Val Phe
20 25
(24) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26
(B) TYPE: amino acids
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:23:
Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Gly Pro Gly Lys Thr
5 10 15
Lys Gly Ser Gly Phe Phe Val Phe Gly Lys Met
20 25
(25) INFORMATION FOR SEQ ID NO:24:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 (B) TYPE: amino acids
(C) STRANDEDNESS: not applicable
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: linking group
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:24:
Pro Pro Xaa Pro Xaa Pro
5
(2) INFORMATION FOR SEQ ID NO:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide Thr Ala Lys Ser Lys Lys Phe Pro Ser Tyr Thr Ala Thr Tyr Gin P 1 5 10 15
(2) INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: Gly He Leu Glu Ser Arg Gly He Lys Ala Arg He Thr His Val A 1 5 10 15
Thr Glu Ser Tyr 20
(2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE:. peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:
Trp Val Arg Asp He He Asp Asp Phe Thr Asn Glu Ser Ser Gin L 1 5 10 15
Thr
(2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
Asp Val Ser Thr He Val Pro Tyr He Gly Pro Ala Leu Asn His V 1 5 10 15
(2) INFORMATION FOR SEQ ID NO:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
Ala Leu Asn He Trp Asp Arg Phe Asp Val Phe Cys Thr Leu Gly A 1 5 10 15
Thr Thr Gly Tyr Leu Lys Gly Asn Ser 20 25
(2) INFORMATION FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:
Asp Ser Glu Thr Ala Asp Asn Leu Glu Lys Thr Val Ala Ala Leu S 1 5 . 10 15
He Leu Pro Gly He Gly Cys 20
(2) INFORMATION FOR SEQ ID NO:31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
5/26365 CΪYUS95/03741
67
( ii ) MOLECULE TYPE : peptide
(xi ) SEQUENCE DESCRIPTION : SEQ ID NO : 31 :
Glu Glu He Val Ala Gin Ser He Ala Leu Ser Ser Leu Met Val A
1 5 10 15
Gin Ala He Pro Leu Val Gly Glu Leu Val Asp He Gly Phe Ala A
20 25 30
Thr Asn Phe Val Glu Ser Cys 35
(2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
Asp He Glu Lys Lys He Ala Lys Met Glu Lys Ala Ser Ser Val P 1 5 10 15
Asn Val Val Asn Ser 20 (2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
Lys Trp Phe Lys Thr Asn Ala Pro Asn Gly Val Asp Glu Lys He A 1 5 10 15
He (2) INFORMATION FOR SEQ ID NO:34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi ) SEQUENCE DESCRIPTION : SEQ ID NO : 34 :
Gly Leu Gin Gly Lys He Ala Asp Ala Val Lys Ala Lys Gly 1 5 10
(2) INFORMATION FOR SEQ ID NO:35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:
Gly Leu Ala Ala Gly Leu Val Gly Met Ala Ala Asp Ala Met Val G 1 5 10 15
Asp Val Asn
(2) INFORMATION FOR SEQ ID NO:36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear (ϋ) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:
Ser Thr Glu Thr Gly Asn Gin His His Tyr Gin Thr Arg Val Val S 1 5- 10 15
Asn Ala Asn Lys 20
(2) INFORMATION FOR SEQ ID NO:37:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:
Lys Lys Gin Tyr He Lys Ala Asn Ser Lys Phe He Gly He Thr G 1 5 10 15
Leu Gly Gly Lys Thr Lys Gly Ser Gly Phe Phe Val Phe
20 25
(2) INFORMATION FOR SEQ ID NO:38:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids . (B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:
Lys Lys Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro L 1 5 10 15
Val Ser Ala Ser His Leu Gly Gly Lys Thr Lys Gly Ser Gly Phe P
20 25 30
Val Phe
(2) INFORMATION FOR SEQ ID NO:39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:
Tyr Met Ser Gly Leu Ala Val Arg Val His Val Ser Lys Glu Glu Gl 1 5 10 15
Gly Lys Thr Lys Gly Ser Gly Phe Phe Val Phe 20 25
(2) INFORMATION FOR SEQ ID NO:40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: .linear (ϋ) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:
Gly He Leu Glu Ser Arg Gly He Lys Ala Arg He Thr His Val As 1 5 10 15
Thr Glu Ser Tyr Gly Gly Lys Thr Lys Gly Ser Gly Phe Phe Val P 20 25 30
(2) INFORMATION FOR SEQ ID NO:41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:
Trp Val Arg Asp He He Asp Asp Phe Thr Asn Glu Ser Ser Gin L
1 5 10 15
Thr Gly Gly Lys Thr Lys Gly Ser Gly Phe Phe Val Phe 20 25
(2) INFORMATION FOR SEQ ID NO:42:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:
Asp Val Ser Thr He Val Pro Tyr He Gly Pro Ala Leu Asn His V 1 5 10 15
Gly Gly Lys Thr Lys Gly Ser Gly Phe Phe Val Phe 20 25
(2) INFORMATION FOR SEQ ID NO:43:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:
Ala Leu Asn He Trp Asp Arg Phe Asp Val Phe Cys Thr Leu Gly A 1 5 10 15
Thr Thr Gly Tyr Leu Lys Gly Asn Ser Gly Gly Lys Thr Lys Gly S
20 25 30
Gly Phe Phe Val Phe 35
(2) INFORMATION FOR SEQ ID NO:44:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:
Asp Ser Glu Thr Ala Asp Asn Leu Glu Lys Thr Val Ala Ala Leu S
1 5 10 15
He Leu Pro Gly He Gly Cys Gly Gly Lys Thr Lys Gly Ser Gly P
20 25 30
Phe Val Phe 35
(2) INFORMATION FOR SEQ ID NO:45:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 amino acids (B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45
Glu Glu He Val Ala Gin Ser He Ala Leu Ser Ser Leu Met Val A
1 5 10 15
Gin Ala He Pro Leu Val Gly Glu Leu Val Asp He Gly Phe Ala A
20 25 30
Thr Asn Phe Val Glu Ser Cys Gly Gly Lys Thr Lys Gly Ser Gly P
35 40 45
Phe Val Phe
50
(2) INFORMATION FOR SEQ ID NO:46:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
o
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:
Asp He Glu Lys Lys He Ala Lys Met Glu Lys Ala Ser Ser Val P 1 5 10 15 Asn Val Val Asn Ser Gly Gly Lys Thr Lys Gly Ser Gly Phe Phe V
20 25 30
Phe
(2) INFORMATION FOR SEQ ID NO:47:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:
Lys Trp Phe Lys Thr Asn Ala Pro Asn Gly Val Asp Glu Lys He A 1 5 10 15
He Gly Gly Lys Thr Lys Gly Ser Gly Phe Phe Val Phe 20 25
(2) INFORMATION FOR SEQ ID NO:48:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:
Gly Leu Gin Gly Lys He Ala Asp Ala Val Lys Ala Lys Gly Gly G 1 5 10 15
Lys Thr Lys Gly Ser Gly Phe Phe Val Phe 20 . 25
(2) INFORMATION FOR SEQ ID NO:49:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:
Gly Leu Ala Ala Gly Leu Val Gly Met Ala Ala Asp Ala Met Val G 1 5 10 15 Asp Val Asn Gly Gly Lys Thr Lys Gly Ser Gly Phe Phe Val Phe
20 25 30
(2) INFORMATION FOR SEQ ID NO:50:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 amino acids (B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:
Ser Thr Glu Thr Gly Asn Gin His His Tyr Gin Thr Arg Val Val Se 1 5 10 15
Asn Ala Asn Lys Gly Gly Lys Thr Lys Gly Ser Gly Phe Phe Val P 20 25 30
(2) INFORMATION FOR SEQ ID NO:51: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:
Phe Phe Leu Leu Thr Arg He Leu Thr He Pro Gin Ser Leu Asp Gl 1 5 10 15
Gly Lys Thr Lys Gly Ser Gly Phe Phe Val Phe 20 25
(2) INFORMATION FOR SEQ ID NO:52:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52
Leu Ser Glu He Lys Gly Val He Val His Arg Leu Glu Gly Val G 1 5 10 15
Gly Lys Thr Lys Gly Ser Gly Phe Phe Val Phe 20 25
(2) INFORMATION FOR SEQ ID NO:53:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:
Lys Lys Leu Arg Arg Leu Leu Tyr Met He Tyr Met Ser Gly Leu A
1 5 10 15
Val Arg Val His Val Ser Lys Glu Glu Gin Tyr Tyr Asp Tyr Gly G
20 25 30
Lys Thr Lys Gly Ser Gly Phe Phe Val Phe 35 40
(2) INFORMATION FOR SEQ ID NO:54
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:
Gly Ala Tyr Ala Arg Cys Pro Asn Gly Thr Arg Ala Leu Thr Val A
1 5 10 15
Glu Leu Arg Gly Asn Ala Glu Leu Gly Gly Lys Thr Lys Gly Ser G
20 . 25 30
Phe Phe Val Phe 35
(2) INFORMATION FOR SEQ ID NO:55:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 54 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:
Thr Ala Lys Ser Lys Lys Phe Pro Ser Tyr Thr Ala Thr Tyr Gin P
1 5 10 15
Gly Gly Gly Ala Tyr Ala Arg Cys Pro Asn Gly Thr Arg Ala Leu T
20 25 30
Val Ala Glu Leu Arg Gly Asn Ala Glu Leu Gly Gly Lys Thr Lys G
35 40 45
Ser Gly Phe Phe Val Phe 50
(2) INFORMATION FOR SEQ ID NO:56:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:
Tyr Asp Pro Asn Tyr Leu Arg Thr Asp Ser Asp Lys Asp Arg Phe L 1 5 10 15 Gin Thr Met Vέtl Lys Leu Phe Asn Asp Arg Phe Leu Gin Thr Met V
20 25 30
Lys Leu Phe Asn Arg He Lys Gly Gly Lys Thr Lys Gly Ser Gly P
35 40 45
Phe Val Phe 50
(2) INFORMATION FOR SEQ ID NO:57:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: .linear (ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:
Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Gly Gly Leu Ser Glu 1 5 10 15
Lys Gly Val He Val His Arg Leu Glu Gly Val 20 25
(2) INFORMATION FOR SEQ ID NO:58:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:
Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Gly Gly Lys Lys Leu A 1 5 10 15 Arg Leu Leu Tyr Met He Tyr Met Ser Gly Leu Ala Val Arg Val H
20 25 30
Val His Lys Glu Glu Gin Tyr Tyr Asp Tyr 35 40
(2) INFORMATION FOR SEQ ID NO:59:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:
Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Gly Gly Gly Ala Tyr A
1 5 10 15
Arg Cys Pro Asn Glu Thr Arg Ala Leu Thr Val Ala Glu Leu Arg G
20 25 30
Asn Ala Glu Leu 35
(2) INFORMATION FOR SEQ ID NO: 60:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 52 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60
Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Gly Gly Tyr Asp Pro
1 5 10 15
Asn Tyr Leu Arg Thr Asp Ser Asp Lys Asp Arg Phe Leu Gin Thr M
20 25 30
Val Lys Leu Phe Asn Asp Arg Phe Leu Gin Thr Met Val Lys Leu P
35 40 45
Asn Arg He Lys 50
(2) INFORMATION FOR SEQ ID NO:61:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61
Leu Ser Glu He Lys Gly Val He Val His Arg Leu Glu Gly Val 1 5 10 15
(2) INFORMATION FOR SEQ ID NO:62
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62
Lys Lys Leu Arg Arg Leu Leu Tyr Met He Tyr Met Ser Gly Leu A
1 5 10 15
Val Arg Val His Val Ser Lys Glu Glu Gin Tyr Tyr Asp Tyr Lys T
20 25 30
Lys Gly Ser Gly Phe Phe Val Phe 35 40
Claims (44)
1. A peptide immunogen represented by the formula:
(A)n- (Th)m- (B)0- (IgE CH4 peptide)p wherein: A is an amino acid, α-NH2, a fatty acid or a derivative thereof, or an invasin; B is an amino acid;
Th is a helper T cell epitope, an analog or segment thereof;
IgE CH4 peptide is SEQ ID NO:l or an immunogenic analog thereof; n is from 1 to 10; m is from 1 to 4; o is from 0 to 10; and p is from 1 to 3.
2. The peptide immunogen of Claim 1 wherein p is 1.
3. The peptide immunogen of Claim 1 wherein Th is selected from the group consisting SEQ ID NOS:5-12, 14, 26-36, 61 and an immunogenic analog or segment thereof.
4. The peptide immunogen of Claim 2 wherein Th is selected from the group consisting SEQ ID NOS:5-12, 14, 26-36, 61 and an immunogenic analog or segment thereof.
5. The peptide immunogen of Claim 1 selected from the group consisting SEQ ID NOS:13, 15-23, 37-50, 51- 56 and 62.
6. The peptide immunogen of Claims 3 selected from the group consisting SEQ ID NOS:51-56 and 62.
7. The peptide immunogen of Claim 1 wherein A is a fatty acid.
8. The peptide immunogen of Claim 2 wherein A is a fatty acid.
9. The peptide immunogen of Claim 1 wherein A is a fatty acid derivative.
10. The peptide immunogen of Claim 2 wherein A is a fatty acid derivative.
11. The peptide immunogen of Claim 9 wherein the fatty acid derivative is Pam3Cys.
12. The peptide immunogen of Claim 10 wherein the fatty acid derivative is Pam3Cys.
13. A vaccine composition comprising an effective amount of a peptide immunogen of Claim 1 in a pharmaceutically acceptable delivery system.
14. A vaccine composition comprising an effective amount of a peptide immunogen of Claim 2 in a pharmaceutically acceptable delivery system.
15. A vaccine composition comprising an effective amount of a peptide immunogen of Claim 3 in a pharmaceutically acceptable delivery system.
16. A vaccine composition comprising an effective amount of a peptide immunogen of Claim 4 in a pharmaceutically acceptable delivery system. 6365
- 80 -
17. A vaccine composition comprising an effective amount of a peptide immunogen of Claim 5 in a pharmaceutically acceptable delivery system.
18. A vaccine composition comprising an effective amount of a peptide immunogen of Claim 6 in a pharmaceutically acceptable delivery system.
19. A vaccine composition comprising an effective amount of a peptide immunogen of Claim 7 in a pharmaceutically acceptable delivery system.
20. A vaccine composition comprising an effective amount of a peptide immunogen of Claim 8 in a pharmaceutically acceptable delivery system.
21. A vaccine composition comprising an effective amount of a peptide immunogen of Claim 9 in a pharmaceutically acceptable delivery system.
22. A vaccine composition comprising an effective amount of a peptide immunogen of Claim 10 in a pharmaceutically acceptable delivery system.
23. A vaccine composition comprising an effective amount of a peptide immunogen of Claim 11 in a pharmaceutically acceptable delivery system.
24. A vaccine composition comprising an effective amount of a peptide immunogen of Claim 12 in a pharmaceutically acceptable delivery system.
25. A vaccine composition comprising an effective amount of a mixture of peptide immunogens of Claim 9 in a pharmaceutically acceptable delivery system.
26. A vaccine composition comprising an effective amount of a mixture of peptide immunogens of Claim 10 in a pharmaceutically acceptable delivery system.
27. A vaccine composition comprising an effective amount of a mixture of peptide immunogens of
Claim 11 in a pharmaceutically acceptable delivery system.
28. A vaccine composition comprising an effective amount of a mixture of peptide immunogens of Claim 12 in a pharmaceutically acceptable delivery system.
29. A method of treating allergic reactions by administering an effective amount of a vaccine composition according to Claim 13.
30. A method of treating allergic reactions by administering an effective amount of a vaccine composition according to Claim 14.
31. A method of treating allergic reactions by administering an effective amount of a vaccine composition according to Claim 15.
32. A method of treating allergic reactions by administering an effective amount of a vaccine composition according to Claim 16.
33. A method of treating allergic reactions by administering an effective amount of a vaccine composition according to Claim 17.
34. A method of treating allergic reactions by administering an effective amount of a vaccine composition according to Claim 18.
° 35. A method of treating allergic reactions by administering an effective amount of a vaccine composition according to Claim 19.
36. A method of treating allergic reactions by administering an effective amount of a vaccine composition according to Claim 20.
37. A method of treating allergic reactions by administering an effective amount of a vaccine composition according to Claim 21.
38. A method of treating allergic reactions by administering an effective amount of a vaccine composition according to Claim 22. 5
39. A method of treating allergic reactions by administering an effective amount of a vaccine composition according to Claim 23.
0 40. A method of treating allergic reactions by administering an effective amount of a vaccine composition according to Claim 24.
41. A method of treating allergic reactions by 5 administering an effective amount of a vaccine composition according to Claim 25.
42. A method of treating allergic reactions by administering an effective amount of a vaccine composition 0 according to Claim 26.
43. A method of treating allergic reactions by administering an effective amount of a vaccine composition according to Claim 27. 5
44. A method of treating allergic reactions by administering an effective amount of a vaccine composition according to Claim 28.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21846194A | 1994-03-28 | 1994-03-28 | |
US218461 | 1994-03-28 | ||
US32891294A | 1994-10-25 | 1994-10-25 | |
US328912 | 1994-10-25 | ||
PCT/US1995/003741 WO1995026365A1 (en) | 1994-03-28 | 1995-03-24 | Synthetic peptide based immunogens for the treatment of allergy |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2195395A true AU2195395A (en) | 1995-10-17 |
Family
ID=26912926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU21953/95A Abandoned AU2195395A (en) | 1994-03-28 | 1995-03-24 | Synthetic peptide based immunogens for the treatment of allergy |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0811016A1 (en) |
JP (1) | JPH09510975A (en) |
CN (1) | CN1146772A (en) |
AU (1) | AU2195395A (en) |
CA (1) | CA2186595A1 (en) |
WO (1) | WO1995026365A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843462A (en) | 1995-11-30 | 1998-12-01 | Regents Of The University Of Minnesota | Diphtheria toxin epitopes |
DE69718150T3 (en) * | 1996-03-01 | 2009-03-05 | Novartis Ag | PEPTIDE IMMUNOGENES FOR THE PROTECTION AGAINST THE TREATMENT OF ALLERGIES |
GB9611673D0 (en) * | 1996-06-05 | 1996-08-07 | Peptide Therapeutics Ltd | Meningococcal vaccine |
WO1999030736A2 (en) | 1997-12-16 | 1999-06-24 | Regents Of The University Of Minnesota | Methods to treat undesirable immune responses |
TWI227241B (en) | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
US6090388A (en) * | 1998-06-20 | 2000-07-18 | United Biomedical Inc. | Peptide composition for prevention and treatment of HIV infection and immune disorders |
US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
AU777952B2 (en) | 1999-04-23 | 2004-11-04 | Pharmexa A/S | Method for down-regulating IL5 activity |
GB9913327D0 (en) * | 1999-06-08 | 1999-08-11 | Smithkline Beecham Biolog | Vaccine |
US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
EP1305339A2 (en) * | 2000-03-15 | 2003-05-02 | Heska Corporation | 3d model of an fc epsilon receptor alpha chain-ige fc region complex |
AU7658101A (en) * | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
IL154219A0 (en) * | 2000-09-06 | 2003-07-31 | Pharmexa As | Method for down-regulating ige |
US7265208B2 (en) | 2001-05-01 | 2007-09-04 | The Regents Of The University Of California | Fusion molecules and treatment of IgE-mediated allergic diseases |
JP2003047482A (en) | 2001-05-22 | 2003-02-18 | Pfizer Prod Inc | IgE VACCINE FREE FROM ANAPHYLAXIS-INDUCING PROPERTY |
WO2003015716A2 (en) | 2001-08-13 | 2003-02-27 | Ige Therapeutics, Inc. | Immunoglobulin e vaccines and methods of use thereof |
IL158287A0 (en) | 2003-10-07 | 2004-05-12 | Yeda Res & Dev | Antibodies to nik, their preparation and use |
US8697846B2 (en) * | 2007-08-15 | 2014-04-15 | Emory University | Methods of making monoclonal antibodies using fusion-peptide epitope adoptive transfer (F-PEAT) technology |
AU2009222974A1 (en) * | 2008-03-13 | 2009-09-17 | Compugen Ltd. | Novel gp96 derived peptides |
WO2013083254A1 (en) | 2011-12-09 | 2013-06-13 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
US9187553B2 (en) * | 2012-01-25 | 2015-11-17 | Swey-Shen Chen | Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold |
JP5918851B2 (en) * | 2012-06-18 | 2016-05-18 | 日本全薬工業株式会社 | IgE peptide vaccine |
EP2790442A1 (en) | 2013-04-09 | 2014-10-15 | Alcatel Lucent | Control system, apparatus, methods, and computer readable storage medium storing instructions for a network node and/or a network controller |
CN112237638B (en) * | 2020-10-28 | 2022-11-29 | 西安华牧生物科技有限责任公司 | Combined probe for reducing radionuclide kidney condensation and preparation method thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8913737D0 (en) * | 1989-06-15 | 1989-08-02 | Univ Birmingham | A novel anti-allergy treatment |
US5552537A (en) * | 1993-03-24 | 1996-09-03 | The Regents Of The University Of California | IgE isoforms and methods of use |
DK0708656T3 (en) * | 1993-04-27 | 2002-12-02 | United Biomedical Inc | Antigenic LHRH peptide constructs and universal synthetic immune stimulators for vaccines |
GB9320897D0 (en) * | 1993-10-11 | 1993-12-01 | Peptide Therapeutics Ltd | Compounds useful in anti-allergy treatment |
GB9417086D0 (en) * | 1994-08-24 | 1994-10-12 | Peptide Therapeutrics Limited | Screen for potential therapeutic compounds |
-
1995
- 1995-03-24 WO PCT/US1995/003741 patent/WO1995026365A1/en not_active Application Discontinuation
- 1995-03-24 JP JP7525239A patent/JPH09510975A/en active Pending
- 1995-03-24 EP EP95914876A patent/EP0811016A1/en not_active Withdrawn
- 1995-03-24 CA CA002186595A patent/CA2186595A1/en not_active Abandoned
- 1995-03-24 CN CN95192778A patent/CN1146772A/en active Pending
- 1995-03-24 AU AU21953/95A patent/AU2195395A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2186595A1 (en) | 1995-10-05 |
EP0811016A1 (en) | 1997-12-10 |
WO1995026365A1 (en) | 1995-10-05 |
JPH09510975A (en) | 1997-11-04 |
EP0811016A4 (en) | 1997-12-10 |
CN1146772A (en) | 1997-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2195395A (en) | Synthetic peptide based immunogens for the treatment of allergy | |
EP1090039B1 (en) | Peptide composition as immunogen for the treatment of allergy | |
CA2329772C (en) | Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens | |
US5759551A (en) | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines | |
EP0708656B1 (en) | Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines | |
WO1994025060A9 (en) | Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines | |
JPH03173830A (en) | Vaccine composition | |
EP1087787A1 (en) | Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic lhrh peptides | |
AU4012095A (en) | Synthetic ige membrane anchor peptide immunogens for the treatment of allergy | |
WO2002051860A2 (en) | Synthetic peptide composition as immunogens for prevention of urinary tract infection | |
MXPA00011938A (en) | Peptide composition as immunogen for the treatment of allergy | |
MXPA00011939A (en) | Artificial t helper cell epitopes as immune stimulators for synthetic peptideimmunogens |